WO2004017920A2 - Novel biphenyl and biphenyl-like cannabinoids - Google Patents

Novel biphenyl and biphenyl-like cannabinoids Download PDF

Info

Publication number
WO2004017920A2
WO2004017920A2 PCT/US2003/026585 US0326585W WO2004017920A2 WO 2004017920 A2 WO2004017920 A2 WO 2004017920A2 US 0326585 W US0326585 W US 0326585W WO 2004017920 A2 WO2004017920 A2 WO 2004017920A2
Authority
WO
WIPO (PCT)
Prior art keywords
ring
alkyl
halogen
present
alkoxy
Prior art date
Application number
PCT/US2003/026585
Other languages
French (fr)
Other versions
WO2004017920B1 (en
WO2004017920A3 (en
Inventor
Alexandros Makriyannis
Xin-Zhong Lai
Dai Lu
Original Assignee
University Of Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Connecticut filed Critical University Of Connecticut
Priority to JP2004531188A priority Critical patent/JP2005536554A/en
Priority to CA002495903A priority patent/CA2495903A1/en
Priority to AU2003265659A priority patent/AU2003265659A1/en
Priority to EP03793389A priority patent/EP1542948A4/en
Publication of WO2004017920A2 publication Critical patent/WO2004017920A2/en
Publication of WO2004017920A3 publication Critical patent/WO2004017920A3/en
Publication of WO2004017920B1 publication Critical patent/WO2004017920B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/13—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
    • C07C205/20—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C215/76—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring
    • C07C215/78—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring containing at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/53—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/15—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings, e.g. phenylphenol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/367—Halogenated derivatives polycyclic non-condensed, containing only six-membered aromatic rings as cyclic parts, e.g. halogenated poly-hydroxyphenylalkanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/56—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups
    • C07C47/57—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/83—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters

Definitions

  • the present invention relates generally to cannabinoid analogs.
  • the invention is more particularly concerned with new and improved biphenyl cannabinoids and the derivative biphenyl-like cannabinoids.
  • the novel compounds exhibit high binding affinities for the CB1 or CB2 cannabinoid receptor.
  • Another aspect of the invention comprises pharmaceutical preparations employing these analogs.
  • a further aspect of the invention comprises a method of administering therapeutically effective amounts of the analogs to provide a physiological effect.
  • Cannabis Sativa, or Marijuana are known to exert behavioral and psychotropic effects but also possess therapeutic properties in a variety of areas such as the central nervous system, the cardiovascular system, the immune system and endocrine system [Kumar RN, et al, Pharmacological actions and therapeutic uses of cannabis and cannabinoids, Anesthesia, 2001 , 56: 1059-1068].
  • the therapeutic applications of most of active cannabinoids are strongly limited by their addictive and psychotropic properties [Nahas G, Marijuana and Medicine: 1999, Human Press Inc., Totowa, NJ].
  • cannabinoid -
  • ⁇ 9 -THC cannabinoid- ⁇ 9 -Tetrahydrocannabinol
  • ⁇ 9 -THC cannabinoid- ⁇ 9 -Tetrahydrocannabinol
  • CB1 two cannabinoid receptors have been characterized: CB1 , a central receptor found in the mammalian brain and a number of other sites in the peripheral tissues and CB2, a peripheral receptor found principally in cells related to the immune system. Characterization of these receptors has been made possible by the development of specific synthetic ligands such as the agonists WIN 55212-2 (aminoalkyl indole) and CP 55,940 (non-classic cannabinoid).
  • cannabinoids such as ⁇ 9 - THC also affect cellular membranes, thereby producing undesirable side effects such as drowsiness, impairment of monoamine oxidase function and impairment of non-receptor mediated brain function.
  • the therapeutic applications of most naturally occurring cannabinoids are limited by their psychotropic properties [Nahas G, Marijuana and Medicine: 1999, Human Press Inc., Totowa, NJ].
  • the CB1 cannabinoid receptor has been detected in the central nervous system (CNS) and in certain peripheral tissues including pituitary gland, immune cells, reproductive organs, gastrointestinal tissues, superior cervical ganglion, heart, lung, urinary bladder and adrenal gland [Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 1997;74(2): 129-80].
  • CNS central nervous system
  • peripheral tissues including pituitary gland, immune cells, reproductive organs, gastrointestinal tissues, superior cervical ganglion, heart, lung, urinary bladder and adrenal gland
  • Pertwee RG Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 1997;74(2): 129-80.
  • the highest expression of CB1 receptors is found in human brain, particularly in cerebellum.
  • the central distribution pattern of CB1 receptors accounts for several prominent pharmacological properties of cannabinoids, such as impairing cognition and memory and alternating the
  • CB1 receptors are also found on pain pathways in brain, spinal cord and at the peripheral terminals of primary sensory neurons [a) Rice AS. Cannabinoids and pain. Curr Opin Investig Drugs. 2001 Mar;2(3):399-414; b) Campbell FA et al, Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ. 2001 Jul 7;323(7303):13-6.], with the latter two presenting attractive targets for separating the analgesic and psychotropic effects of cannabinoids.
  • the CB2 cannabinoid receptor does not appear to be expressed within the CNS but is the predominant form of the cannabinoid receptor expressed within immune system.
  • CB2 receptor Significant presence of CB2 receptor has been detected in human tonsils, leukocytes, and spleen [Galiegue S et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995 Aug 15;232(1 ):54-61]. In human leukocytes, CB2 receptors were found with particularly high concentration in B-cells, natural killer cells and macrophage. The significant and predominant presence of cannabinoid receptor CB2 subtype in immune system suggest that CB2 receptor could be the most likely cannabinoid receptor that mediates the immunomodulatory effects of cannabinoids.
  • cannabinoid receptors were followed by the demonstration of the existence of endogenous cannabinoid receptor agonists such as arachidonoylethanolamide (anandamide) and 2-arachidonoylglycerol (2-AG) [Maccarron M., Endocannabinoids and their actions. Vitamins and Hormones 2002;65:225-255]. There is evidence that both these compounds can serve as neuromodulators or neurotransmitters.
  • Biological organization of the endogenous cannabinoid system includes the CB1 and CB2 receptors, their endogenous ligands and the multiple metabolic pathways for the synthesis, degradation and reuptake of the endogenous ligands. Both anandamide and 2-AG are synthesized by neurones on demand.
  • anandamide is hydrolysed to arachidonic acid and ethanolamine by the microsomal enzyme, fatty acid amide hydrolase (FAAH).
  • FAAH fatty acid amide hydrolase
  • one aspect of the present invention comprises novel biphenyl cannabinoids and the derivative biphenyl-like cannabinoids.
  • Some of the inventive compounds are a group of potent cannabimimetic ligands possessing high cannabinoid receptor affinity and CB2 receptor selectivity. Compared to the classical cannabinoids and the endogenous cannabinoid receptor ligands anandamide and 2-arachidonyl glycerol, some of the biphenyl compounds and the derivative biphenyl-like cannabinoids are more potent, more stable and easier to prepare. Some of the compounds also possess considerable selectivity mostly for the CB2 receptor.
  • the "A" ring atoms of compound formula I comprise carbon and 0 to 2 nitrogen heteroatoms.
  • Ar is an aromatic ring, an aromatic ring comprising at least one substituent group, a heteroaromatic ring, a heteroaromatic ring comprising 1 to 5 substituent groups, a heterocyclic ring or a heterocyclic ring comprising at least one substituent group.
  • R comprises H, OH, OCH 3) alkoxy, OCH 2 CH 2 OH, alcohol, NH 2 , P0 3 H, OPO 3 H, OS0 3 H, halogen, C(halogen) 3 .
  • SE.,, OE ⁇ or NE 1 E 2 , E 1 and E 2 are each independently H or alkyl.
  • R' comprises H, OH, alkoxy, OCH 2 CH 2 OH, alcohol, NH 2 , PO 3 H, OP0 3 H, OSO 3 H, halogen, C(halogen) 3 , SE-i, OE1 or NE 1 E 2 , E 1 and E 2 are each independently H or alkyl.
  • R", R'" and R"" each independently comprises Y-D ⁇ -D 2 -T 2 , H, halogen, alkyl, alkoxy or a substituent group as defined later.
  • D 1 is optionally present and if present comprises alkyl
  • D 2 comprises H, alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic, a tricyclic ring, an aromatic or heteroaromatic ring,
  • T 2 is optionally present and if present comprises an aromatic ring, a substituted aromatic ring, a heteroaromatic ring, a substituted heteroaromatic ring, a heterocyclic ring, a substituted heterocyclic ring, H, OH, halogen, or a substituent group as defined later;
  • R m and R"" comprises Y-D D 2 -T 2 and the others of R", R'" and R"" each independently comprise H, halogen, alkyl, alkoxy or a substituent group as defined later.
  • R' comprises H, halogen, C(halogen) 3 , lower alkyl or alkoxy
  • R" comprises H, halogen, C(halogen) 3) lower alkyl or alkoxy; and R" comprises -Y-D ⁇ -D 2 -T 2 ,
  • Y comprises C(CH 3 ) 2 . CH 2 or CH(CH 3 ),
  • Di is optionally present and if present comprises alkyl, D 2 comprises H, an alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring or a heteroaromatic ring,
  • T 2 is optionally present and if present comprises an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen or a substituent group.
  • R' comprises H, halogen, C(halogen) 3 , lower alkyl or alkoxy
  • R" comprises H, halogen, C(halogen) 3 , lower alkyl or alkoxy
  • R" comprises -Y-D ⁇ -D 2 -T 2
  • Y comprises O, NH or N-alkyl
  • Di is optionally present and if present comprises alkyl
  • D 2 comprises H, an alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring or a heteroaromatic ring,
  • T 2 is optionally present and if present comprises an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen or a substituent group.
  • R' comprises H, halogen, C(halogen) 3 , lower alkyl or alkoxy
  • R" comprises H, halogen, C(halogen) 3 , lower alkyl or alkoxy
  • D 2 comprises H, alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring or a heteroaromatic ring,
  • T 2 is optionally present and if present comprises an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen or a substituent group.
  • R' comprises H, halogen, C(halogen) 3 , lower alkyl or alkoxy
  • R" comprises H, halogen, C(halogen) 3 , lower alkyl or alkoxy; and R" comprises -Y-D ⁇ -D 2 -T 2 ,
  • Y comprises 0 to 1 of a carbocyclic ring having 4 to 6 ring members or a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms.
  • Di is optionally present and if present comprises alkyl
  • D 2 comprises H, alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring or a heteroaromatic ring, T 2 is optionally present and if present comprises an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen or a substituent group.
  • Ar comprises an aromatic ring having 5 or 6 ring members or a heteroaromatic ring having 5 or 6 ring members.
  • Ar comprises one of the structures:
  • the Ar aromatic ring structure comprises 0 to 3 heteroatoms as ring members.
  • Ar comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 1-, 2- or 3-morpholinyl, 1-, 2- or 3-thiomorpholinyl, 1-, 2- or 3- azetidinyl, 1-, or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on any available ring carbon thereof by alkyl; or any above group unsubstituted on one or more nitrogen atoms, or any above group substituted on one or more nitrogen atoms independently by an alkyl, benzyl, lower-alkoxybenzyl or benzhydryl group; adamantyl; a carbocyclic ring, a substituted carbocyclic ring, a heteroaromatic ring, a substituted heteroaromatic ring, a heterocyclic ring, a substituted heterocyclic ring, a bicyclic ring, a substituted bicyclic ring, a substituted bicyclic
  • G comprises H, OH, NH 2 , halogen, N 3 , NO 2 , NCS, CF 3 , CHO, OAc,
  • R" When Ar is 4-isopropyl pyridine or 4-isopropenyl pyridine; R'" is hydrogen; and R"" is hydrogen, then R" can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms.
  • R" can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms.
  • R" is C(CH 3 ) 2 (CH 2 )5CH 3
  • R 2 and R 4 are methyl.
  • R' and R" can not be H, OH or OCH 3 .
  • acyl refers to the general formula -C(O)alkyl.
  • acyloxy refers to the general formula -O-acyl.
  • alcohol refers to the general formula alkyl-OH and includes primary, secondary and tertiary variations.
  • alkyl refers to a linear, branched or cyclic alkyl group having from 1 to about 16 carbon atoms including, for example, methyl, ethyl, propyl, butyl, hexyl, octyl, isopropyl, isobutyl, tert-butyl, cyclopropyl, cyclohexyl, cyclooctyl, vinyl and allyl.
  • an alkyl group can be saturated or unsaturated. Unless otherwise specifically limited an alkyl group can be unsubstituted, singly substituted, or multiply substituted, with substituent groups in any possible position.
  • a cyclic alkyl group may include monocyclic, bicyclic, tricyclic, tetracyclic and polycyclic rings, for example norbornyl, adamantyl and related terpenes.
  • alkoxy refers to the general formula -O-alkyl.
  • alkylmercapto refers to the general formula -S-alkyl.
  • alkylamino refers to the general formula -(NH)-alkyl.
  • di-alkylamino refers to the general formula -N-(alkyl) 2 . Unless otherwise specifically limited di-alkylamino includes cyclic amine compounds such as piperidine and morpholine. Unless otherwise specifically defined, an aromatic ring is an unsaturated ring structure having about 5 to about 7 ring members and including only carbon as ring atoms. Unless otherwise specifically defined, an aromatic ring can be unsubstituted, singly substituted, or multiply substituted, with substituent groups in any possible position. Unless otherwise specifically defined, "aryl” refers to an aromatic ring system that includes only carbon as ring atoms, for example phenyl, biphenyl or naphthyl. Unless otherwise specifically limited an aryl moiety can be unsubstituted, singly substituted, or multiply substituted, with substituent groups in any possible position. Unless otherwise specifically defined, “aroyl” refers to the general formula
  • a bicyclic ring structure comprises 2 fused or bridged rings that include only carbon as ring atoms.
  • the bicyclic ring structure may be saturated or unsaturated.
  • a bicyclic ring structure can be unsubstituted, singly substituted, or multiply substituted, with substituent groups in any possible position.
  • the individual rings may or may not be of the same type.
  • Examples of bicyclic ring structures include, Dimethyl-bicyclo[3,1 ,1] heptane, bicyclo[2,2,1]heptadiene, decahydro-naphthalene and bicyclooctane.
  • a carbocyclic ring is a non-aromatic ring structure having about 3 to about 8 ring members, substituted or unsubstituted, that includes only carbon as ring atoms, for example, cyclohexadiene or cyclohexane. Unless otherwise specifically limited a carbocyclic ring structure can be unsubstituted, singly substituted, or multiply substituted, with substituent groups in any possible position.
  • halogen refers to an atom selected from fluorine, chlorine, bromine and iodine.
  • a heteroaromatic ring is an unsaturated ring structure having about 5 to about 8 ring members that has carbon atoms and one or more heteroatoms, including oxygen, nitrogen and/or sulfur, as ring atoms, for example, pyridine, furan, quinoline, and their derivatives.
  • a heteroaromatic ring can be unsubstituted, singly substituted, or multiply substituted, with substituent groups in any possible position.
  • a heterobicyclic ring structure comprises 2 fused or bridged rings that include carbon and one or more heteroatoms, including oxygen, nitrogen and/or sulfur, as ring atoms.
  • the heterobicyclic ring structure is saturated or unsaturated.
  • the heterobicyclic ring structure can be unsubstituted, singly substituted, or multiply substituted, with substituent groups in any possible position.
  • the individual rings may or may not be of the same type. Examples of heterobicyclic ring structures include tropane, quinuclidine and tetrahydro-benzofuran.
  • a heterocyclic ring is a saturated ring structure having about 3 to about 8 ring members that has carbon atoms and one or more heteroatoms, including oxygen, nitrogen and/or sulfur, as ring atoms, for example, piperidine, morpholine, piperazine, pyrrolidine, thiomorpholine, tetrahydropyridine, and their derivatives.
  • the heterocyclic ring can be unsubstituted, singly substituted, or multiply substituted, with substituent groups in any possible position.
  • a heterotricyclic ring structure comprises 3 rings that may be fused, bridged or both, and that include carbon and one or more heteroatoms, including oxygen, nitrogen and/or sulfur, as ring atoms.
  • the heterotricyclic ring structure can be saturated or unsaturated.
  • the heterotricyclic ring structure can be unsubstituted, singly substituted, or multiply substituted, with substituent groups in any possible position.
  • the individual rings may or may not be of the same type. Examples of heterotricyclic ring structures include 2,4,10-trioxaadamantane, tetradecahydro-phenanthroline.
  • a heteropolycyclic ring structure comprises more than 3 rings that may be fused, bridged or both and that includes carbon and one or more heteroatoms, including oxygen, nitrogen and/or sulfur, as ring atoms.
  • the heteropolycyclic ring structure can be saturated or unsaturated.
  • the heteropolycyclic ring structure can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position.
  • the individual rings may or may not be of the same type.
  • Examples of heteropolycyclic ring structures include azaadamantine, 5-norbornene-2,3- dicarboximide.
  • phenacyl refers to the general formula -phenyl-acyl.
  • a polycyclic ring structure comprises more than 3 rings that may be fused, bridged or both fused and bridged and that includes carbon as ring atoms.
  • the polycyclic ring structure can be saturated or unsaturated.
  • a polycyclic ring structure can be unsubstituted, singly substituted, or multiply substituted, with substituent groups in any possible position.
  • the individual rings may or may not be of the same type.
  • Examples of polycyclic ring structures include adamantine, bicyclooctane, norbomane and bicyclononanes.
  • a spirocycle refers to a ring system wherein a single atom is the only common member of two rings.
  • a spirocycle can comprise a saturated carbocyclic ring comprising about 3 to about 8 ring members, a heterocyclic ring comprising about 3 to about 8 ring atoms wherein up to about 3 ring atoms may be N, S, or O or a combination thereof.
  • a tricyclic ring structure comprises 3 rings that may be fused, bridged or both fused and bridged and that includes carbon as ring atoms.
  • the tricyclic ring structure can be saturated or unsaturated.
  • the tricyclic ring structure can be unsubstituted, singly substituted, or if possible, multiply substituted, with substituent groups in any possible position.
  • the individual rings may or may not be of the same type.
  • Examples of tricyclic ring structures include fluorene and anthracene.
  • substituted means substituted by at least one below described substituent group in any possible position or positions.
  • Substituent groups for the above moieties useful in the invention are those groups that do not significantly diminish the biological activity of the inventive compound.
  • Substituent groups that do not significantly diminish the biological activity of the inventive compound include, for example, H, halogen, N3, NCS, CN, NO 2 , NX ⁇ X 2 , OX 3 , C(X 3 ) 3 , OAc, O-acyl, O-aroyl, NH-acyl, NH-aroyl, NHCOalkyl, CHO, C(halogen) 3 , COOX3, SO 3 H, PO 3 H 2 .
  • X 1 and X 2 each independently comprise H or alkyl, or X 1 and X 2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members and X 3 comprises H, alkyl, loweralkylhydroxy, or alkyl-NX ⁇ X 2 .
  • a substituent group may be in any possible position or any possible positions if multiply substituted.
  • inventive biphenyl and biphenyl-like cannabinoid compounds exhibit high affinity for the CB1 and/or CB2 cannabinoid receptors.
  • another aspect of the invention is use of at least one of the inventive compounds to interact with cannabinoid receptors.
  • some of the inventive biphenyl and biphenyl-like cannabinoid compounds show a very high selectivity for one of the cannabinoid receptors.
  • inventive selective compounds are able to interact with one cannabinoid receptor, for example the CB2 cannabinoid receptor, without affecting the other cannabinoid receptor to the same degree. Therefore, still another aspect of the invention is use of at least one of the inventive compounds to preferentially interact with one cannabinoid receptor.
  • inventive biphenyl and biphenyl-like cannabinoid compounds can act as high affinity modulators for cannabinoid receptors.
  • the inventive cannabinoid compounds therefore are potential therapeutic agents through the modulation of the CB1 and/or CB2 cannabinoid receptors.
  • Some of the inventive biphenyl and biphenyl-like cannabinoid compounds described herein may be cannabinoid receptor agonists.
  • the inventive cannabinoid agonists interact with the CB1 and/or CB2 cannabinoid receptor binding site to initiate a physiological or a pharmacological response characteristic of that receptor. Therefore, a further aspect of the invention is use of at least one of the inventive compounds to initiate an agonistic response from a cannabinoid receptor.
  • inventive biphenyl and biphenyl-like cannabinoid compounds described herein may be cannabinoid receptor antagonists.
  • the inventive cannabinoid antagonists interact with the CB1 and/or CB2 cannabinoid receptor binding site to block other ligands from the receptor binding site without initiating a physiological or a pharmacological response characteristic of that receptor.
  • cannabinoid antagonists typically oppose the cannabinoid receptor site response characteristics initiated by cannabinoid agonists. Therefore, a further aspect of the invention is use of at least one of the inventive compounds to oppose initiation of an agonistic response from a cannabinoid receptor.
  • inventive biphenyl and biphenyl-like cannabinoid compounds described herein, and physiologically acceptable salts thereof have pharmacological properties when administered in therapeutically effective amounts for providing a physiological response in individuals and/or animals.
  • another aspect of the invention is the administration of a therapeutically effective amount of at least one of the inventive compounds, or a physiologically acceptable salt thereof, to an individual or animal to provide a physiological response.
  • Some of the novel biphenyl and biphenyl-like compounds in this invention are also more polar (less lipophilic) than known cannabinoids, a property that may help to improve their therapeutic usefulness in certain applications.
  • novel biphenyl and biphenyl-like cannabinoids described herein, and physiologically acceptable salts thereof have pharmacological properties when administered in therapeutically effective amounts for providing a physiological effect useful to treat central and peripheral pain, neuropathy, neurodegenerative diseases including multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease; mental disorders such as schizophrenia and depression; to prevent or reduce endotoxic shock and hypotensive shock; to modulate appetite; to modulate the immune system; to reduce fertility; to prevent or reduce diseases associated with motor function such as Tourette's syndrome; to prevent or reduce inflammation; to provide neuroprotection and to suppress memory and produce peripheral vasodilation; to treat epilepsy, glaucoma, nausea associated with cancer chemotherapy and AIDS wasting syndrome as well as other ailments in which cannabinoid system is implicated.
  • the invention involves the administration of a therapeutically effective amount of an inventive compound, or a physiologically acceptable salt thereof, to an individual or animal to provide a physiological effect.
  • compositions of the invention may be alternately formulated to comprise, consist of, or consist essentially of, any appropriate components herein disclosed.
  • compositions of the invention may additionally, or alternatively, be formulated so as to be devoid, or substantially free, of any components, materials, ingredients, adjuvants or species used in the prior art compositions or that are otherwise not necessary to the achievement of the function and/or objectives of the present invention.
  • a "therapeutically effective amount" of a compound is the quantity of a compound which, when administered to an individual or animal, results in a sufficiently high level of that compound in the individual or animal to cause a discernible increase or decrease in stimulation of cannabinoid receptors.
  • Physiological effects that result from cannabinoid receptor stimulation include analgesia, decreased nausea resulting from chemotherapy, sedation and increased appetite.
  • Other physiological effects that result from cannabinoid receptor stimulation include relieving intraocular pressure in glaucoma patients and suppression of the immune system.
  • a “therapeutically effective amount” of the compound ranges from about 10 mg/day to about 1 ,000 mg/day.
  • an "individual” refers to a human.
  • An “animal” refers to, for example, veterinary animals, such as dogs, cats, horses and the like, and farm animals, such as cows, pigs and the like.
  • the compound of the present invention can be administered by a variety of known methods, including orally, rectally, or by parenteral routes (e.g., intramuscular, intravenous, subcutaneous, nasal or topical).
  • parenteral routes e.g., intramuscular, intravenous, subcutaneous, nasal or topical.
  • the form in which the compounds are administered will be determined by the route of administration.
  • Such forms include, but are not limited to, capsular and tablet formulations (for oral and rectal administration), liquid formulations (for oral, intravenous, intramuscular, subcutaneous ocular, intranasal, inhalation based or transdermal administration) and slow releasing microcarriers (for rectal, intramuscular or intravenous administration).
  • the formulations can also contain a physiologically acceptable vehicle and optional adjuvants, flavorings, colorants and preservatives.
  • Suitable physiologically acceptable vehicles may include, for example, saline, sterile water, Ringer's solution and isotonic sodium chloride solutions.
  • the specific dosage level of active ingredient will depend upon a number of factors, including, for example, biological activity of the particular preparation, age, body weight, sex and general health of the individual being treated.
  • inventive compounds are generally represented by compound formula
  • biphenyl cannabinoids A number of different biphenyl cannabinoids were prepared. Biphenyl cannabinoids synthesized with different functional groups are depicted in Table 1. TABLE 1
  • binding affinity is represented by the K,- value which is the inhibition constant correlated with the concentration of an analog required to occupy the 50% of the total number (Bmax) of the receptors. The lower the ,- value, the higher the binding affinity.
  • an analog is said to have "binding selectivity” if it has higher binding affinity for one receptor compared to the other receptor; e.g. a cannabinoid analog which has an ,- of 0.1 nM for CB2 and 10 nM for CB1, is 100 times more selective for the CB2 receptor.
  • TME Tris-HCI buffer, 5 mM MgCI 2 and 1 mM EDTA
  • the treated membranes were subsequently used in the binding assay described below. Approximately 30 ⁇ g of membranes were incubated in silanized 96-well microtiter plate with TME containing 0.1% essentially fatty acid-free bovine serum albumin (BSA), 0.8 nM [ 3 H] CP-55,940, and various concentrations of test materials in a final volume of 200 ⁇ L. The assays were incubated for 1 hour at 30 °C and then immediately filtered using Packard Filtermate 196 harvester and Whatman GF/C filterplates and washed with wash buffer (TME) containing 0.5% BSA.
  • BSA essentially fatty acid-free bovine serum albumin
  • Radioactivity was detected using MicroScint 20 scintillation cocktail added directly to the dried filterplates, and the filterplates were counted using a Packard Instruments Top-Count. Nonspecific binding was assessed using 100 nM CP- 55,940. Data collected from three independent experiments performed with duplicate determinations was normalized between 100% and 0% specific binding for [ 3 H] CP-55,940, determined using buffer and 100nM CP-55,940. The normalized data was analyzed using a 4-parameter nonlinear logistic equation to yield IC 50 values.
  • Trimethylborate, tetrakis(triphenylphosphine)palladium, barium hydroxide octahydrate, boron tribromide, boron triiodide, sodium carbonate and n-butyllithium were also purchased from the Aldrich Chemical Company. Purification by flash chromatograph was carried out on silica gel, grade 9385 (230-400 mesh) using solvents indicated in the parenthesis as eluents. Thin layer chromatographic analyses were carried out on Whatman 60F 25 polyester plates.
  • the common intermediate 5 can be synthesized by the Suzuki coupling reaction, either from aryl bromide 1 and commercially available boronic acid 2 or from aryl boronic acid 3 and widely commercially available aryl bromide 4.
  • Multiply substituted aryl boronic acid or multiply substituted aryl bromide can be used in Scheme 1 to prepare the inventive compounds having multiply substituted Ar rings.
  • the mixture was heated in an oil bath at 80 °C with stirring untill the boronic acid 3 could no longer be detected in the reaction mixture. Subsequently, the reaction mixture was cooled, and subjected to filtration through a short silica gel. The filtrate was treated with saturated NaCI solution, dried (Na2SO 4 ) and evaporated. The residue was purified by flash column chromatography on silica gel with petroleum ether/acetone (100:1.5-2) to afford the biaryl dimethoxyether 5.

Abstract

Novel biphenyl and biphenyl-like cannabinoid compounds are presented. These compounds, when administered in a therapeutically effective amount to an individual or animal, result in a sufficiently high level of that compound in the individual or animal to cause a physiological response. The physiological response useful to treat a number of physiological conditions.

Description

Novel Biphenyl And Biphenyl-like Cannabinoids
Cross Reference to Related Applications
This application claims the benefit of United States Provisional Application No. 60/405,608, filed 8/23/2002, the contents of each of which are incorporated by reference in their entirety.
Statement Regarding Federally Sponsored Research or Development
This invention was made with Government support under Contract No. DA3801 awarded by the National Institute of Health. The Government has certain rights in the invention.
Field of the Invention
The present invention relates generally to cannabinoid analogs. The invention is more particularly concerned with new and improved biphenyl cannabinoids and the derivative biphenyl-like cannabinoids. In some embodiments the novel compounds exhibit high binding affinities for the CB1 or CB2 cannabinoid receptor. Another aspect of the invention comprises pharmaceutical preparations employing these analogs. A further aspect of the invention comprises a method of administering therapeutically effective amounts of the analogs to provide a physiological effect.
Background of the Invention
The active components of Cannabis Sativa, or Marijuana, are known to exert behavioral and psychotropic effects but also possess therapeutic properties in a variety of areas such as the central nervous system, the cardiovascular system, the immune system and endocrine system [Kumar RN, et al, Pharmacological actions and therapeutic uses of cannabis and cannabinoids, Anesthesia, 2001 , 56: 1059-1068]. The therapeutic applications of most of active cannabinoids are strongly limited by their addictive and psychotropic properties [Nahas G, Marijuana and Medicine: 1999, Human Press Inc., Totowa, NJ].
Representative classical cannabinoid (-)-Δ9-Tetrahydrocannabinol (Δ9-THC) is the major active constituent extracted from Cannabis Sativa (Marijuana). The pharmacological effects of cannabinoids pertain to a variety of areas such as the central nervous system, the cardiovascular system, the immune system and endocrine system. Most of the effects of cannabinoids are due to an interaction with specific high-affinity receptors. Presently, two cannabinoid receptors have been characterized: CB1 , a central receptor found in the mammalian brain and a number of other sites in the peripheral tissues and CB2, a peripheral receptor found principally in cells related to the immune system. Characterization of these receptors has been made possible by the development of specific synthetic ligands such as the agonists WIN 55212-2 (aminoalkyl indole) and CP 55,940 (non-classic cannabinoid).
In addition to acting at the cannabinoid receptors, cannabinoids such as Δ9- THC also affect cellular membranes, thereby producing undesirable side effects such as drowsiness, impairment of monoamine oxidase function and impairment of non-receptor mediated brain function. The therapeutic applications of most naturally occurring cannabinoids are limited by their psychotropic properties [Nahas G, Marijuana and Medicine: 1999, Human Press Inc., Totowa, NJ].
The CB1 cannabinoid receptor has been detected in the central nervous system (CNS) and in certain peripheral tissues including pituitary gland, immune cells, reproductive organs, gastrointestinal tissues, superior cervical ganglion, heart, lung, urinary bladder and adrenal gland [Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 1997;74(2): 129-80]. The highest expression of CB1 receptors is found in human brain, particularly in cerebellum. The central distribution pattern of CB1 receptors accounts for several prominent pharmacological properties of cannabinoids, such as impairing cognition and memory and alternating the control of motor function, and mediating the psychotropic effects and other neurobehavioral effects of cannabinoids. CB1 receptors are also found on pain pathways in brain, spinal cord and at the peripheral terminals of primary sensory neurons [a) Rice AS. Cannabinoids and pain. Curr Opin Investig Drugs. 2001 Mar;2(3):399-414; b) Campbell FA et al, Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ. 2001 Jul 7;323(7303):13-6.], with the latter two presenting attractive targets for separating the analgesic and psychotropic effects of cannabinoids. Conversely, the CB2 cannabinoid receptor does not appear to be expressed within the CNS but is the predominant form of the cannabinoid receptor expressed within immune system. Significant presence of CB2 receptor has been detected in human tonsils, leukocytes, and spleen [Galiegue S et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995 Aug 15;232(1 ):54-61]. In human leukocytes, CB2 receptors were found with particularly high concentration in B-cells, natural killer cells and macrophage. The significant and predominant presence of cannabinoid receptor CB2 subtype in immune system suggest that CB2 receptor could be the most likely cannabinoid receptor that mediates the immunomodulatory effects of cannabinoids. The immune modulatory effects of cannabinoids are considerably broad, such as altering immune cell proliferation and function, altering antibody formation and altering cytokine production [a) Kaminski NE et al, Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cvclase modulation within the immune system. Toxicol Appl Pharmacol. 1997 Feb; 142(2):278-87; b) Berdyshev EV, Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids. 2000 Nov; 108(1 -2): 169-90; c) Kaminski NE, Regulation of the cAMP cascade, gene expression and immune function by cannabinoid receptors. J Neuroimmunol. 1998 Mar 15;83(1 -2): 124-32; d) Klein TW et al, The cannabinoid system and cytokine network. Proc Soc Exp Biol Med. 2000 Oct; 225(1 ): 1-8; e) Klein TW et al, Cannabinoid receptors and immunity. Immunol Today. 1998 Aug; 19(8):373-81; f) Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids. 2000 Nov; 108(1 -2): 169-90].
The discovery of cannabinoid receptors was followed by the demonstration of the existence of endogenous cannabinoid receptor agonists such as arachidonoylethanolamide (anandamide) and 2-arachidonoylglycerol (2-AG) [Maccarron M., Endocannabinoids and their actions. Vitamins and Hormones 2002;65:225-255]. There is evidence that both these compounds can serve as neuromodulators or neurotransmitters. Biological organization of the endogenous cannabinoid system includes the CB1 and CB2 receptors, their endogenous ligands and the multiple metabolic pathways for the synthesis, degradation and reuptake of the endogenous ligands. Both anandamide and 2-AG are synthesized by neurones on demand. They can undergo depolarization-induced release from neurons. After their release and interaction with the receptors, they are rapidly removed from the extracellular space by a membrane transport process yet to be fully characterized [Beltramo M., Functional role of high-affinitv anandamide transport, as revealed by selective inhibition. Science 1997; 277(5329): 1094- 1097]. Once within the cell, anandamide is hydrolysed to arachidonic acid and ethanolamine by the microsomal enzyme, fatty acid amide hydrolase (FAAH). The amplitude and duration of fatty acid amide signals can be regulated in vivo primarily by this integral membrane protein. Recently, the crystal structure of this enzyme was reported [Bracey, M et al, Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling. Science 2002; 298(5599): 1793-1796.]. 2-AG can also be hydrolyzed enzymatically, both by fatty acid amide hydrolase (FAAH) and by monoacylglycerol (MAG) lipase [Ueda, N., Endocannabinoid hydrolases. Prostaglandins & Other Lipid Mediators 2002;68- 69:521-534.].
Summary of the Invention
Briefly stated, one aspect of the present invention comprises novel biphenyl cannabinoids and the derivative biphenyl-like cannabinoids. Some of the inventive compounds are a group of potent cannabimimetic ligands possessing high cannabinoid receptor affinity and CB2 receptor selectivity. Compared to the classical cannabinoids and the endogenous cannabinoid receptor ligands anandamide and 2-arachidonyl glycerol, some of the biphenyl compounds and the derivative biphenyl-like cannabinoids are more potent, more stable and easier to prepare. Some of the compounds also possess considerable selectivity mostly for the CB2 receptor.
The compounds described in this invention are generally represented by compound formula I.
One embodiment of the invention comprises compound formula I
Figure imgf000005_0001
The "A" ring atoms of compound formula I comprise carbon and 0 to 2 nitrogen heteroatoms.
Ar is an aromatic ring, an aromatic ring comprising at least one substituent group, a heteroaromatic ring, a heteroaromatic ring comprising 1 to 5 substituent groups, a heterocyclic ring or a heterocyclic ring comprising at least one substituent group.
R comprises H, OH, OCH3) alkoxy, OCH2CH2OH, alcohol, NH2, P03H, OPO3H, OS03H, halogen, C(halogen)3. SE.,, OEΪ or NE1E2, E1 and E2 are each independently H or alkyl.
R' comprises H, OH, alkoxy, OCH2CH2OH, alcohol, NH2, PO3H, OP03H, OSO3H, halogen, C(halogen)3, SE-i, OE1 or NE1E2, E1 and E2 are each independently H or alkyl.
R", R'" and R"" each independently comprises Y-Dι-D2-T2, H, halogen, alkyl, alkoxy or a substituent group as defined later.
Y is optionally present and if present comprises O, S, NH, N-alkyl, C=CH, C≡C, CH2, CH(CH3), C(CH3)2. a carbocyclic ring having 4 to 6 ring members or a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms.
D1 is optionally present and if present comprises alkyl,
D2 comprises H, alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic, a tricyclic ring, an aromatic or heteroaromatic ring,
T2 is optionally present and if present comprises an aromatic ring, a substituted aromatic ring, a heteroaromatic ring, a substituted heteroaromatic ring, a heterocyclic ring, a substituted heterocyclic ring, H, OH, halogen, or a substituent group as defined later;
In one variation advantageous for cannabimimetic activity only one of R", Rm and R"" comprises Y-D D2-T2 and the others of R", R'" and R"" each independently comprise H, halogen, alkyl, alkoxy or a substituent group as defined later.
In another variation advantageous for cannabimimetic activity: R'" comprises H, halogen, C(halogen)3, lower alkyl or alkoxy;
R"" comprises H, halogen, C(halogen)3) lower alkyl or alkoxy; and R" comprises -Y-Dι-D2-T2,
Y comprises C(CH3)2. CH2 or CH(CH3),
Di is optionally present and if present comprises alkyl, D2 comprises H, an alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring or a heteroaromatic ring,
T2 is optionally present and if present comprises an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen or a substituent group.
In another variation advantageous for cannabimimetic activity: R'" comprises H, halogen, C(halogen)3, lower alkyl or alkoxy; R"" comprises H, halogen, C(halogen)3, lower alkyl or alkoxy; and R" comprises -Y-Dι-D2-T2,
Y comprises O, NH or N-alkyl,
Di is optionally present and if present comprises alkyl,
D2 comprises H, an alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring or a heteroaromatic ring,
T2 is optionally present and if present comprises an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen or a substituent group.
In another variation advantageous for cannabimimetic activity:
R'" comprises H, halogen, C(halogen)3, lower alkyl or alkoxy; R"" comprises H, halogen, C(halogen)3, lower alkyl or alkoxy; and R" comprises -Y-O^^-T , Y is optionally present and if present comprises C=CH or C≡C, Di is optionally present and if present comprises alkyl,
D2 comprises H, alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring or a heteroaromatic ring,
T2 is optionally present and if present comprises an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen or a substituent group.
In another advantageous variation R'" comprises H, halogen, C(halogen)3, lower alkyl or alkoxy;
R"" comprises H, halogen, C(halogen)3, lower alkyl or alkoxy; and R" comprises -Y-Dι-D2-T2,
Y comprises 0 to 1 of a carbocyclic ring having 4 to 6 ring members or a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms.
Di is optionally present and if present comprises alkyl,
D2 comprises H, alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring or a heteroaromatic ring, T2 is optionally present and if present comprises an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen or a substituent group.
In one variation of the invention Ar comprises an aromatic ring having 5 or 6 ring members or a heteroaromatic ring having 5 or 6 ring members.
In another variation of the invention Ar comprises one of the structures:
Figure imgf000008_0001
The Ar aromatic ring structure comprises 0 to 3 heteroatoms as ring members. R1 , R2, R3, R4 and R5, if present, each independently comprise H, OH,
NH2) halogen, N3, N02, NCS, C(halogen)3, CHO, OAc, OCH3, OC2H5. CH2OH, CH2CH2OH, CH2CH2CH2OH, CN, C(=0)CH3, COOH, COOCH3, COOC2H5, COOCH(CH3)2, NHCOCHs, SCH3, SC2H5, NHCH3, CH2NH2, CH3, C2H5- C3H7, C2H3, ethynyl, alkoxy, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl, alkylsulfonyl or methylene dioxy or other substituent groups as defined later
In another variation of the invention Ar comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 1-, 2- or 3-morpholinyl, 1-, 2- or 3-thiomorpholinyl, 1-, 2- or 3- azetidinyl, 1-, or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on any available ring carbon thereof by alkyl; or any above group unsubstituted on one or more nitrogen atoms, or any above group substituted on one or more nitrogen atoms independently by an alkyl, benzyl, lower-alkoxybenzyl or benzhydryl group; adamantyl; a carbocyclic ring, a substituted carbocyclic ring, a heteroaromatic ring, a substituted heteroaromatic ring, a heterocyclic ring, a substituted heterocyclic ring, a bicyclic ring, a substituted bicyclic ring, a heterobicyclic ring, a substituted heterobicyclic ring, a polycyclic ring, a substituted polycyclic ring, a heteropolycyclic ring or a substituted heteropolycyclic ring.
In an advantageous variation of the invention Ar comprises:
Figure imgf000009_0001
G comprises H, OH, NH2, halogen, N3, NO2, NCS, CF3, CHO, OAc,
OCH3, OC2H5, CH2OH, CH2CH2OH, CH2CH2CH2OH, CN, C(=O)CH3,
COOH, COOCH3> COOC2H5, COOCH(CH3)2- NHCOCH3, SCH3, SC2H5,
NHCH3, CH2NH2. CH3, C2H5, C3H7, C2H3, ethynyl, alkoxy, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl, alkylsulfonyl or methylene dioxy.
Provisos with respect to compound formula I:
When Ar is 4-isopropyl pyridine or 4-isopropenyl pyridine; R'" is hydrogen; and R"" is hydrogen, then R" can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms.
When Ar is 4-isopropyl toluene or 4-isopropenyl toluene, and both R'" and R"" are hydrogen, R" can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms.
When R" is C(CH3)2(CH2)5CH3, R2 and R4 are methyl. R' and R" can not be H, OH or OCH3.
Unless otherwise specifically defined, "acyl" refers to the general formula -C(O)alkyl.
Unless otherwise specifically defined, "acyloxy" refers to the general formula -O-acyl.
Unless otherwise specifically defined, "alcohol" refers to the general formula alkyl-OH and includes primary, secondary and tertiary variations.
Unless otherwise specifically defined, "alkyl" or "lower alkyl" refers to a linear, branched or cyclic alkyl group having from 1 to about 16 carbon atoms including, for example, methyl, ethyl, propyl, butyl, hexyl, octyl, isopropyl, isobutyl, tert-butyl, cyclopropyl, cyclohexyl, cyclooctyl, vinyl and allyl. Unless otherwise specifically defined, an alkyl group can be saturated or unsaturated. Unless otherwise specifically limited an alkyl group can be unsubstituted, singly substituted, or multiply substituted, with substituent groups in any possible position. Unless otherwise specifically limited, a cyclic alkyl group may include monocyclic, bicyclic, tricyclic, tetracyclic and polycyclic rings, for example norbornyl, adamantyl and related terpenes. Unless otherwise specifically defined, "alkoxy" refers to the general formula -O-alkyl.
Unless otherwise specifically defined, "alkylmercapto" refers to the general formula -S-alkyl. Unless otherwise specifically defined, "alkylamino" refers to the general formula -(NH)-alkyl.
Unless otherwise specifically defined, "di-alkylamino" refers to the general formula -N-(alkyl)2. Unless otherwise specifically limited di-alkylamino includes cyclic amine compounds such as piperidine and morpholine. Unless otherwise specifically defined, an aromatic ring is an unsaturated ring structure having about 5 to about 7 ring members and including only carbon as ring atoms. Unless otherwise specifically defined, an aromatic ring can be unsubstituted, singly substituted, or multiply substituted, with substituent groups in any possible position. Unless otherwise specifically defined, "aryl" refers to an aromatic ring system that includes only carbon as ring atoms, for example phenyl, biphenyl or naphthyl. Unless otherwise specifically limited an aryl moiety can be unsubstituted, singly substituted, or multiply substituted, with substituent groups in any possible position. Unless otherwise specifically defined, "aroyl" refers to the general formula
-C(=O)-aryl.
Unless otherwise specifically defined, a bicyclic ring structure comprises 2 fused or bridged rings that include only carbon as ring atoms. The bicyclic ring structure may be saturated or unsaturated. Unless otherwise specifically limited a bicyclic ring structure can be unsubstituted, singly substituted, or multiply substituted, with substituent groups in any possible position. The individual rings may or may not be of the same type. Examples of bicyclic ring structures include, Dimethyl-bicyclo[3,1 ,1] heptane, bicyclo[2,2,1]heptadiene, decahydro-naphthalene and bicyclooctane. Unless otherwise specifically defined, a carbocyclic ring is a non-aromatic ring structure having about 3 to about 8 ring members, substituted or unsubstituted, that includes only carbon as ring atoms, for example, cyclohexadiene or cyclohexane. Unless otherwise specifically limited a carbocyclic ring structure can be unsubstituted, singly substituted, or multiply substituted, with substituent groups in any possible position.
Unless otherwise specifically defined, "halogen" refers to an atom selected from fluorine, chlorine, bromine and iodine. Unless otherwise specifically defined, a heteroaromatic ring is an unsaturated ring structure having about 5 to about 8 ring members that has carbon atoms and one or more heteroatoms, including oxygen, nitrogen and/or sulfur, as ring atoms, for example, pyridine, furan, quinoline, and their derivatives. Unless otherwise specifically limited a heteroaromatic ring can be unsubstituted, singly substituted, or multiply substituted, with substituent groups in any possible position.
Unless otherwise specifically defined, a heterobicyclic ring structure comprises 2 fused or bridged rings that include carbon and one or more heteroatoms, including oxygen, nitrogen and/or sulfur, as ring atoms. The heterobicyclic ring structure is saturated or unsaturated. The heterobicyclic ring structure can be unsubstituted, singly substituted, or multiply substituted, with substituent groups in any possible position. The individual rings may or may not be of the same type. Examples of heterobicyclic ring structures include tropane, quinuclidine and tetrahydro-benzofuran. Unless otherwise specifically defined, a heterocyclic ring is a saturated ring structure having about 3 to about 8 ring members that has carbon atoms and one or more heteroatoms, including oxygen, nitrogen and/or sulfur, as ring atoms, for example, piperidine, morpholine, piperazine, pyrrolidine, thiomorpholine, tetrahydropyridine, and their derivatives. The heterocyclic ring can be unsubstituted, singly substituted, or multiply substituted, with substituent groups in any possible position.
Unless otherwise specifically defined, a heterotricyclic ring structure comprises 3 rings that may be fused, bridged or both, and that include carbon and one or more heteroatoms, including oxygen, nitrogen and/or sulfur, as ring atoms. The heterotricyclic ring structure can be saturated or unsaturated. The heterotricyclic ring structure can be unsubstituted, singly substituted, or multiply substituted, with substituent groups in any possible position. The individual rings may or may not be of the same type. Examples of heterotricyclic ring structures include 2,4,10-trioxaadamantane, tetradecahydro-phenanthroline.
Unless otherwise specifically defined, a heteropolycyclic ring structure comprises more than 3 rings that may be fused, bridged or both and that includes carbon and one or more heteroatoms, including oxygen, nitrogen and/or sulfur, as ring atoms. The heteropolycyclic ring structure can be saturated or unsaturated. The heteropolycyclic ring structure can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position. The individual rings may or may not be of the same type. Examples of heteropolycyclic ring structures include azaadamantine, 5-norbornene-2,3- dicarboximide.
Unless otherwise specifically defined, the term "phenacyl" refers to the general formula -phenyl-acyl.
Unless otherwise specifically defined, a polycyclic ring structure comprises more than 3 rings that may be fused, bridged or both fused and bridged and that includes carbon as ring atoms. The polycyclic ring structure can be saturated or unsaturated. Unless otherwise specifically limited a polycyclic ring structure can be unsubstituted, singly substituted, or multiply substituted, with substituent groups in any possible position. The individual rings may or may not be of the same type. Examples of polycyclic ring structures include adamantine, bicyclooctane, norbomane and bicyclononanes.
Unless otherwise specifically defined, a spirocycle refers to a ring system wherein a single atom is the only common member of two rings. A spirocycle can comprise a saturated carbocyclic ring comprising about 3 to about 8 ring members, a heterocyclic ring comprising about 3 to about 8 ring atoms wherein up to about 3 ring atoms may be N, S, or O or a combination thereof.
Unless otherwise specifically defined, a tricyclic ring structure comprises 3 rings that may be fused, bridged or both fused and bridged and that includes carbon as ring atoms. The tricyclic ring structure can be saturated or unsaturated. The tricyclic ring structure can be unsubstituted, singly substituted, or if possible, multiply substituted, with substituent groups in any possible position. The individual rings may or may not be of the same type. Examples of tricyclic ring structures include fluorene and anthracene. Unless otherwise specifically limited the term substituted means substituted by at least one below described substituent group in any possible position or positions. Substituent groups for the above moieties useful in the invention are those groups that do not significantly diminish the biological activity of the inventive compound. Substituent groups that do not significantly diminish the biological activity of the inventive compound include, for example, H, halogen, N3, NCS, CN, NO2, NXιX2, OX3, C(X3)3, OAc, O-acyl, O-aroyl, NH-acyl, NH-aroyl, NHCOalkyl, CHO, C(halogen)3, COOX3, SO3H, PO3H2. SO2NW2, CONX1X2, alkyl, alcohol, alkoxy, alkylmercapto, alkylamino, di-alkylamino, sulfonamide or thioalkoxy wherein X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members and X3 comprises H, alkyl, loweralkylhydroxy, or alkyl-NXιX2. Unless otherwise specifically limited, a substituent group may be in any possible position or any possible positions if multiply substituted.
Some of the inventive biphenyl and biphenyl-like cannabinoid compounds exhibit high affinity for the CB1 and/or CB2 cannabinoid receptors. Thus, another aspect of the invention is use of at least one of the inventive compounds to interact with cannabinoid receptors.
Further, some of the inventive biphenyl and biphenyl-like cannabinoid compounds show a very high selectivity for one of the cannabinoid receptors.
These inventive selective compounds are able to interact with one cannabinoid receptor, for example the CB2 cannabinoid receptor, without affecting the other cannabinoid receptor to the same degree. Therefore, still another aspect of the invention is use of at least one of the inventive compounds to preferentially interact with one cannabinoid receptor.
Some of the inventive biphenyl and biphenyl-like cannabinoid compounds can act as high affinity modulators for cannabinoid receptors. The inventive cannabinoid compounds therefore are potential therapeutic agents through the modulation of the CB1 and/or CB2 cannabinoid receptors. Some of the inventive biphenyl and biphenyl-like cannabinoid compounds described herein may be cannabinoid receptor agonists. The inventive cannabinoid agonists interact with the CB1 and/or CB2 cannabinoid receptor binding site to initiate a physiological or a pharmacological response characteristic of that receptor. Therefore, a further aspect of the invention is use of at least one of the inventive compounds to initiate an agonistic response from a cannabinoid receptor.
Some of the inventive biphenyl and biphenyl-like cannabinoid compounds described herein may be cannabinoid receptor antagonists. The inventive cannabinoid antagonists interact with the CB1 and/or CB2 cannabinoid receptor binding site to block other ligands from the receptor binding site without initiating a physiological or a pharmacological response characteristic of that receptor. Thus, cannabinoid antagonists typically oppose the cannabinoid receptor site response characteristics initiated by cannabinoid agonists. Therefore, a further aspect of the invention is use of at least one of the inventive compounds to oppose initiation of an agonistic response from a cannabinoid receptor.
The inventive biphenyl and biphenyl-like cannabinoid compounds described herein, and physiologically acceptable salts thereof, have pharmacological properties when administered in therapeutically effective amounts for providing a physiological response in individuals and/or animals. Thus, another aspect of the invention is the administration of a therapeutically effective amount of at least one of the inventive compounds, or a physiologically acceptable salt thereof, to an individual or animal to provide a physiological response. Some of the novel biphenyl and biphenyl-like compounds in this invention are also more polar (less lipophilic) than known cannabinoids, a property that may help to improve their therapeutic usefulness in certain applications.
The novel biphenyl and biphenyl-like cannabinoids described herein, and physiologically acceptable salts thereof, have pharmacological properties when administered in therapeutically effective amounts for providing a physiological effect useful to treat central and peripheral pain, neuropathy, neurodegenerative diseases including multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease; mental disorders such as schizophrenia and depression; to prevent or reduce endotoxic shock and hypotensive shock; to modulate appetite; to modulate the immune system; to reduce fertility; to prevent or reduce diseases associated with motor function such as Tourette's syndrome; to prevent or reduce inflammation; to provide neuroprotection and to suppress memory and produce peripheral vasodilation; to treat epilepsy, glaucoma, nausea associated with cancer chemotherapy and AIDS wasting syndrome as well as other ailments in which cannabinoid system is implicated. Thus, the invention involves the administration of a therapeutically effective amount of an inventive compound, or a physiologically acceptable salt thereof, to an individual or animal to provide a physiological effect.
The inventive compounds include any and all isomers and steroisomers. In general, the compositions of the invention may be alternately formulated to comprise, consist of, or consist essentially of, any appropriate components herein disclosed. The compositions of the invention may additionally, or alternatively, be formulated so as to be devoid, or substantially free, of any components, materials, ingredients, adjuvants or species used in the prior art compositions or that are otherwise not necessary to the achievement of the function and/or objectives of the present invention.
A better understanding of the invention will be obtained from the following detailed description of the presently preferred, albeit illustrative, embodiments of the invention.
Description of Some Preferred Embodiments
As used herein a "therapeutically effective amount" of a compound, is the quantity of a compound which, when administered to an individual or animal, results in a sufficiently high level of that compound in the individual or animal to cause a discernible increase or decrease in stimulation of cannabinoid receptors. Physiological effects that result from cannabinoid receptor stimulation include analgesia, decreased nausea resulting from chemotherapy, sedation and increased appetite. Other physiological effects that result from cannabinoid receptor stimulation include relieving intraocular pressure in glaucoma patients and suppression of the immune system. Typically, a "therapeutically effective amount" of the compound ranges from about 10 mg/day to about 1 ,000 mg/day. As used herein, an "individual" refers to a human. An "animal" refers to, for example, veterinary animals, such as dogs, cats, horses and the like, and farm animals, such as cows, pigs and the like.
The compound of the present invention can be administered by a variety of known methods, including orally, rectally, or by parenteral routes (e.g., intramuscular, intravenous, subcutaneous, nasal or topical). The form in which the compounds are administered will be determined by the route of administration. Such forms include, but are not limited to, capsular and tablet formulations (for oral and rectal administration), liquid formulations (for oral, intravenous, intramuscular, subcutaneous ocular, intranasal, inhalation based or transdermal administration) and slow releasing microcarriers (for rectal, intramuscular or intravenous administration). The formulations can also contain a physiologically acceptable vehicle and optional adjuvants, flavorings, colorants and preservatives. Suitable physiologically acceptable vehicles may include, for example, saline, sterile water, Ringer's solution and isotonic sodium chloride solutions. The specific dosage level of active ingredient will depend upon a number of factors, including, for example, biological activity of the particular preparation, age, body weight, sex and general health of the individual being treated.
The following examples are given for purposes of illustration only in order that the present invention may be more fully understood. These examples are not intended to limit in any way the scope of the invention unless otherwise specifically indicated.
Examples: The inventive compounds are generally represented by compound formula
I and include physiologically acceptable salts thereof.
A number of different biphenyl cannabinoids were prepared. Biphenyl cannabinoids synthesized with different functional groups are depicted in Table 1. TABLE 1
Figure imgf000018_0001
TABLE 1 (continued)
Figure imgf000019_0001
Figure imgf000019_0002
TABLE 1 (continued)
Figure imgf000020_0001
Figure imgf000020_0002
Figure imgf000020_0003
Figure imgf000020_0004
Figure imgf000020_0005
TABLE 1 (continued)
Figure imgf000021_0001
Figure imgf000021_0002
Some inventive analogs were tested for CB2 receptor binding affinity and for CB1 receptor affinity (to determine selectivity). As used herein, "binding affinity" is represented by the K,- value which is the inhibition constant correlated with the concentration of an analog required to occupy the 50% of the total number (Bmax) of the receptors. The lower the ,- value, the higher the binding affinity. As used herein an analog is said to have "binding selectivity" if it has higher binding affinity for one receptor compared to the other receptor; e.g. a cannabinoid analog which has an ,- of 0.1 nM for CB2 and 10 nM for CB1, is 100 times more selective for the CB2 receptor. For the CB1 receptor binding studies, membranes were prepared from rat forebrain membranes according to the procedure of P.R. Dodd et al, A Rapid Method for Preparing Svnaptosomes: Comparison with Alternative Procedures, Brain Res., 107 - 118 (1981). The binding of the novel analogues to the CB1 cannabinoid receptor was assessed as described in W.A. Devane et al, Determination and Characterization of a Cannabinoid Receptor in a Rat Brain. Mol. Pharmacol., 34, 605 - 613 (1988) and A. Charalambous et al, 5'-azido Δ8-THC: A Novel Photoaffinitv Label for the Cannabinoid Receptor, J. Med. Chem., 35, 3076 - 3079 (1992) with the following changes. The above articles are incorporated by reference herein.
Membranes, previously frozen at -80°C, were thawed on ice. To the stirred suspension was added three volumes of TME (25 mM Tris-HCI buffer, 5 mM MgCI2 and 1 mM EDTA) at a pH 7.4. The suspension was incubated at 4°C for 30 min. At the end of the incubation, the membranes were pelleted and washed three times with TME.
The treated membranes were subsequently used in the binding assay described below. Approximately 30 μg of membranes were incubated in silanized 96-well microtiter plate with TME containing 0.1% essentially fatty acid-free bovine serum albumin (BSA), 0.8 nM [3H] CP-55,940, and various concentrations of test materials in a final volume of 200 μL. The assays were incubated for 1 hour at 30 °C and then immediately filtered using Packard Filtermate 196 harvester and Whatman GF/C filterplates and washed with wash buffer (TME) containing 0.5% BSA. Radioactivity was detected using MicroScint 20 scintillation cocktail added directly to the dried filterplates, and the filterplates were counted using a Packard Instruments Top-Count. Nonspecific binding was assessed using 100 nM CP- 55,940. Data collected from three independent experiments performed with duplicate determinations was normalized between 100% and 0% specific binding for [3H] CP-55,940, determined using buffer and 100nM CP-55,940. The normalized data was analyzed using a 4-parameter nonlinear logistic equation to yield IC50 values. Data from at least two independent experiments performed in duplicate was used to calculate IC50 values which were converted to Kj values using the assumptions of Cheng et al, Relationship Between the Inhibition Constant (Kι) and the concentration of Inhibitor which causes 50% Inhibition (ICml of an Enzymatic Reaction, Biochem. Pharmacol., 22, 3099-3102, (1973), which is incorporated by reference herein.
For the CB2 receptor binding studies, membranes were prepared from frozen mouse spleen essentially according to the procedure of P.R. Dodd et al, A Rapid Method for Preparing Svnaptosomes: Comparison with Alternative Procedures, Brain Res., 226, 107 - 118 (1981) which is incorporated by reference herein. Silanized centrifuge tubes were used throughout to minimize receptor loss due to adsorption. The CB2 binding assay was conducted in the same manner as for the CB1 binding assay. The binding affinities (Kj) were also expressed in nanomoles (nM). TABLE 2 lists binding affinities for some of the inventive compounds.
Figure imgf000023_0001
Typical Preparation Procedures
The inventive compounds were prepared by the Suzuki Coupling (Scheme 1 and 2). The following examples are given for purposes of illustration only in order that the present invention may be more fully understood. These examples are not intended to limit in any way to the practice of the invention.
The preparation procedures include aspects of the following references, the disclosures of which are hereby incorporated by reference. Alo, B.I.; Kandil, A.; Patil, P. A.; Sharp, M. J.; Siddiqui, M. A.; and Snieckus, V. Seguential Directed Ortho Metalation-Boronic Acid Cross-Coupling Reactions. A general Regiospecific Route to Oxygenerated Dibenzofb,dlpyran-6-ones Related to Ellagic Acid, J. Org. Chem. 1991, 56, 3763-3768. Watanabe, T.; Miyaura, N.; Suzuki, A., Synthesis of Sterically Hindered Bian ls via the Palladium Catalyzed Cross-Coupling Reaction of Arylboronic Acids or their Esters with Haloarenes, Synlett 1992, 207-210. Morris, S,; Mechoulam, R.; and Irene, Y., Halogenation of phenols and Phenyl ethers with Potassium Halides in the Presence of 18-Crown-6 on Oxidation with m-Chloroperbenzoic Acid, J. Chem. Soc, Perkin Trans. 1 1987, 1423-1427. Gareau, Y.; Dufresne, C; Gallant, M.; Rochette, C; Sawyer, N.; Slipetz, D. M.; Tremblay, N.; Weech, P. K.; Metters, K. M.; Labelle, M. Structure activity relationships of tetrahydrocanabinol analogs on human cannabinoid receptors. Bioorg. Med. Chem. Lett. 1996, 6(2), 89-94. Beak, P.; and Brown, R A., The Tertiary Amide as an Effective Director of Ortho Lithiation, J. Org. Chem. 1982, 47, 34-36. Rhee, M. H.; Vogel, Z.; Barg, J.; Bayewitch, M.; Levy, R.; Hanus, L.; Breuer, A.; and Mechoulam, R., Cannabinol Derivatives: Binding to Cannabinoid Receptors and Inhibition of Adenylcvclase, J. Med. Chem. 1997, 40, 3228-3233. Fahrenholtz, K. E., Lurie, M. and Kierstead, AR. W., The Total Synthesis of α7-Δ9- Tetrahvdrocannabinol and Four of Its Isomers. J. Amer. Chem. Soc. 1967, 89:23, 5934-5941. Love, R. Bender, P. E., Dowalo, F., Macko, E., and Fowler, P., Cannabinoids. Structure-Activity Studies Related to 1 ,2-Dimethylheptyl Derivatives, J. Med. Chem 1973, 16, 1200-1206. Scheme 1
Figure imgf000025_0001
Scheme 2
Figure imgf000025_0002
Figure imgf000025_0003
General. Proton NMR spectrums were recorded on Bruker 200MHz and 500MHz spectrometers as solutions in deuterated chloroform or other suitable solvents. Routine GC-MS analyses of the intermediates and the final products were performed on a Hewlett-Packard 6890A series gas chromatograph coupled with a mass selective detector (MSD). Anhydrous tetrahydrofuran (THF) and anhydrous ethylene glycol dimethyl ether (dimethoxyethane, or DME) were purchased from the Aldrich Chemical Company. DME was degassed using argon for the Suzuki coupling reaction. Trimethylborate, tetrakis(triphenylphosphine)palladium, barium hydroxide octahydrate, boron tribromide, boron triiodide, sodium carbonate and n-butyllithium were also purchased from the Aldrich Chemical Company. Purification by flash chromatograph was carried out on silica gel, grade 9385 (230-400 mesh) using solvents indicated in the parenthesis as eluents. Thin layer chromatographic analyses were carried out on Whatman 60F25 polyester plates. As indicated in Scheme 1 , the common intermediate 5 can be synthesized by the Suzuki coupling reaction, either from aryl bromide 1 and commercially available boronic acid 2 or from aryl boronic acid 3 and widely commercially available aryl bromide 4. Multiply substituted aryl boronic acid or multiply substituted aryl bromide can be used in Scheme 1 to prepare the inventive compounds having multiply substituted Ar rings.
General procedure for the synthesis of Biaryl dimethoxyether 5 from the commercial available Aryl boronic acid 2:
To a suspension of Pd(PPh3)4 (0.05 Equiv) in anhydrous DME was added the arylbromide 1 and the mixture was stirred for 10 min at room temperature. To this solution were added sequentially the arylboronic acid 2 (1.5 equiv) in a minimum of EtOH and aqueous Na2CO3 (2 M solution, 2.0 equiv), and the mixture was refluxed for 18 hour, cooled, and subjected to filtration through a short silica gel. The filtrate was treated with saturated NaCI solution, dried (Na2S04) and evaporated. The residue was purified by flash column chromatography on silica gel with petroleum ether / acetone (100:1.5 ~ 2) to afford the Biaryl dimethoxyether 5. Intermediate 3
A solution of 1 (2.78 g, 8 mmol) in 8 ml of THF was stirred and cooled to - 78 °C under N2. The solution (1.6 M in Hexane) of n-BuLi (5.5 ml, 8.8 mmol, 1.1 equiv) was added dropwise over 30 min. The reaction mixture was stirred for an additional 15 min at -78 °C, treated with B(OMe)3 (2.7 ml, 24 mmol, 3 equiv) and allowed to warm to room temperature over 12 h. it was cooled 0 °C and acidified to pH 6.5 with 5% aqueous HCI, and extracted with methylene chloride. The organic layer was washed with saturated brine solution, dried (Na2SO4) and evaporated. The residue was purified by flash column chromatography on silica gel with petroleum ether / acetone (100: 12) to afford the colorless solid Intermediate 3 (2.1 g, 85% yield).
General procedure for the synthesis of Biaryl dimethoxyether 5 from the commercial available Aryl halide 4: To a flask equipped with a reflux condenser, a septum inlet, and a magnetic stirring bar, were added Pd(PPh3)4 (0.05 Equiv), the boronic acid 3 (1 equiv), and Ba(OH)2-8H2θ (1.5 equiv). The flask was flushed with Nitrogen and charged with DME (6 ml/mmol 3), H O (1 ml/mmol 3) and aryl halide 4 (1.2 equiv) through the septum inlet with a syringe. The mixture was heated in an oil bath at 80 °C with stirring untill the boronic acid 3 could no longer be detected in the reaction mixture. Subsequently, the reaction mixture was cooled, and subjected to filtration through a short silica gel. The filtrate was treated with saturated NaCI solution, dried (Na2SO4) and evaporated. The residue was purified by flash column chromatography on silica gel with petroleum ether/acetone (100:1.5-2) to afford the biaryl dimethoxyether 5.
General procedure for the synthesis of Biaryl compounds
A solution of the biaryl dimethoxyether 5 (0.25 M) in CH2CI2was stirred and cooled in an ice bath. Boron tribromide (2.5 Equiv, 1 M in CH2CI2) was added dropwise. The mixture was stirred at 0 °C for 4 h and the reaction was quenched by adding H20 slowly at 0 °C. The mixture was then diluted with ether, washed
(saturated NaCI), dried (Na2SO4) and evaporated. The residue was purified by flash column chromatography on silica gel with petroleum ether / acetone (100: 12 ~ 20) to afford the Biaryl 6.
The synthesis of compound 12 represented biphenyls was carried out by
Suzuki coupling via an ortho-amide facilitated reaction as described by Watanabe, T.; Miyaura, N.; and Suzuki, A., in Synthesis of Sterically Hindered Biaryls via the
Palladium Catalyzed Cross-Coupling Reaction of Arylboronic Acids or their Esters with Haloarenes, Synlett 1992, 207-210.
Those skilled in the art will recognize, or be able to ascertain with no more than routine experimentation, many equivalents to the specific embodiments of the invention disclosed herein. Such equivalents are intended to be encompassed by the scope of the invention.

Claims

What is claimed is:
1. A compound of formula I below, and physiologically acceptable salts, comprising:
Figure imgf000029_0001
wherein the "A" ring atoms of compound formula I comprise carbon and 0 to 2 nitrogen heteroatoms;
Ar is an aromatic ring, an aromatic ring comprising at least one substituent group, a heteroaromatic ring, a heteroaromatic ring comprising 1 to 5 substituent groups, a heterocyclic ring or a heterocyclic ring comprising at least one substituent group;
R comprises H, OH, OCH3, alkoxy, OCH2CH2OH, alcohol, NH2, PO3H, OPO3H, OSO3H, halogen, C(halogen)3, SE-j, OE1 orNE1E2, E1 and E2 are each independently H or alkyl;
R' comprises H, OH, alkoxy, OCH2CH2OH, alcohol, NH2, PO3H, OPO3H, OSO3H, halogen, C(halogen)3, SE-i, OE1 orNE1E2,
E1 and E2 are each independently H or alkyl;
R", R'" and R"" each independently comprises Y-Dι-D2-T2, H, halogen, alkyl, alkoxy or a substituent group,
Y is optionally present and if present comprises O, S, NH, N-alkyl, C=CH, C≡C, CH2, CH(CH3), C(CH3)2, a carbocyclic ring having 4 to 6 ring members or a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms, Di is optionally present and if present comprises alkyl,
D2 comprises H, alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic, a tricyclic ring, an aromatic or heteroaromatic ring,
T2 is optionally present and if present comprises an aromatic ring, a substituted aromatic ring, a heteroaromatic ring, a substituted heteroaromatic ring, a heterocyclic ring, a substituted heterocyclic ring, H, OH, halogen, or a substituent group;
with the proviso that, when Ar is 4-isopropyl pyridine or 4-isopropenyl pyridine, R"' is hydrogen, and R"" is hydrogen, then R" can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms; when Ar is 4-isopropyl toluene or 4-isopropenyl toluene, and both R'" and R"" are hydrogen, R" can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms; when R" is C(CH3)2(CH2)5CH3, R2 and R are methyl, then R' and R" can not be H, OH or OCH3.
2. The compound of claim 1 wherein only one of R", R'" and R"" comprises Y- D1-D2-T2 and the others of R", R'" and R"" each independently comprise H, halogen, alkyl, alkoxy or a substituent group.
3. The compound of claim 1 wherein:
R'" comprises H, halogen, C(halogen)3, lower alkyl or alkoxy;
R"" comprises H, halogen, C(halogen)3, lower alkyl or alkoxy; and
R" comprises -Y-D D2-T2,
Y comprises C(CH3)2. CH2 or CH(CH3),
Di is optionally present and if present comprises alkyl,
D2 comprises H, an alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring or a heteroaromatic ring, T2 is optionally present and if present comprises an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen or a substituent group.
4. The compound of claim 1 wherein:
R'" comprises H, halogen, C(halogen)3, lower alkyl or alkoxy; R"" comprises H, halogen, C(haIogen)3, lower alkyl or alkoxy; and R" comprises -Y-Dι-D2-T2,
Y comprises O, NH or N-alkyl,
Di is optionally present and if present comprises alkyl,
D2 comprises H, an alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring or a heteroaromatic ring,
T2 is optionally present and if present comprises an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen or a substituent group.
5. The compound of claim 1 wherein:
R'" comprises H, halogen, C(halogen)3, lower alkyl or alkoxy; R"" comprises H, halogen, C(halogen)3, lower alkyl or alkoxy; and R" comprises -Y-Dι-D2-T2,
Y is optionally present and if present comprises C=CH or C≡C, Di is optionally present and if present comprises alkyl,
D2 comprises H, alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring or a heteroaromatic ring,
T2 is optionally present and if present comprises an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen or a substituent group.
6. The compound of claim 1 wherein:
R'" comprises H, halogen, C(halogen)3, lower alkyl or alkoxy; R"" comprises H, halogen, C(halogen)3, lower alkyl or alkoxy; and R" comprises -Y-Dι-D -T2,
Y comprises 0 to 1 of a carbocyclic ring having 4 to 6 ring members or a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms.
D-i is optionally present and if present comprises alkyl,
D2 comprises H, alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring or a heteroaromatic ring,
T2 is optionally present and if present comprises an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen or a substituent group.
7. The compound of claim 1 wherein Ar comprises an aromatic ring having 5 or 6 ring members or a heteroaromatic ring having 5 or 6 ring members.
8. The compound of claim 1 wherein Ar comprises one of the structures:
Figure imgf000032_0001
and, the Ar aromatic ring structure comprises 0 to 3 heteroatoms as ring members;
R1 , R2, R3, R4 and R5 each independently comprise H, OH, NH2, halogen, N3, NO2> NCS, C(halogen)3, CHO, OAc, OCH3, OC2H5. CH2OH, CH2CH2OH, CH2CH2CH2OH, CN, C(=O)CH3, COOH, COOCH3, COOC2H5, COOCH(CH3)2, NHCOCH3, SCH3, SC2H5, NHCH3, CH2NH2, CH3, C2H5) C3H7, C2H3, ethynyl, alkoxy, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl, alkylsulfonyl or methylene dioxy or a substituent group.
9. The compound of claim 1 wherein Ar comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 1-, 2- or 3-morpholinyl, 1-, 2- or 3-thiomorpholinyl, 1-, 2- or 3- azetidinyl, 1-, or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on any available ring carbon thereof by alkyl; or any above group unsubstituted on one or more nitrogen atoms, or any above group substituted on one or more nitrogen atoms independently by an alkyl, benzyl, lower-alkoxybenzyl or benzhydryl group; adamantyl; a carbocyclic ring, a substituted carbocyclic ring, a heteroaromatic ring, a substituted heteroaromatic ring, a heterocyclic ring, a substituted heterocyclic ring, a bicyclic ring, a substituted bicyclic ring, a heterobicyclic ring, a substituted heterobicyclic ring, a polycyclic ring, a substituted polycyclic ring, a heteropolycyclic ring or a substituted heteropolycyclic ring.
10. The compound of claim 1 wherein Ar comprises:
Figure imgf000033_0001
G comprises H, OH, NH2, halogen, N3, NO2, NCS, CF3, CHO, OAc, OCH3, OC2H5, CH2OH, CH2CH2OH, CH2CH2CH2OH, CN, C(=O)CH3, COOH, COOCH3, COOC2H5, COOCH(CH3)2, NHCOCH3, SCH3, SC2H5, NHCH3, CH2NH2, CH3, C2H5, C3H7, C2H3, ethynyl, alkoxy, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl, alkylsulfonyl or methylene dioxy.
11. A pharmaceutical preparation comprising a therapeutically effective amount of at least one compound of formula I below, and physiologically acceptable salts thereof:
Figure imgf000034_0001
wherein, the "A" ring atoms of compound formula I comprise carbon and 0 to 2 nitrogen heteroatoms;
Ar is an aromatic ring, an aromatic ring comprising at least one substituent group, a heteroaromatic ring, a heteroaromatic ring comprising 1 to 5 substituent groups, a heterocyclic ring or a heterocyclic ring comprising at least one substituent group;
R comprises H, OH, OCH3, alkoxy, OCH2CH2OH, alcohol, NH2, PO3H, OP03H, OSO3H, halogen, C(halogen)3, SE-i, OE-, or NE1E2) E1 and E2 are each independently H or alkyl;
R' comprises H, OH, alkoxy, OCH2CH2OH, alcohol, NH2, PO3H, OPO3H, OSO3H, halogen, C(halogen)3, SEι, orNEιE2,
E1 and E2 are each independently H or alkyl;
R", R'" and R"" each independently comprises Y-Dι-D2-T2, H, halogen, alkyl, alkoxy or a substituent group,
Y is optionally present and if present comprises O, S, NH, N-alkyl, C=CH,
C≡C, CH2, CH(CH3), C(CH3)2, a carbocyclic ring having 4 to 6 ring members or a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms,
Di is optionally present and if present comprises alkyl, D2 comprises H, alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic, a tricyclic ring, an aromatic or heteroaromatic ring,
T2 is optionally present and if present comprises an aromatic ring, a substituted aromatic ring, a heteroaromatic ring, a substituted heteroaromatic ring, a heterocyclic ring, a substituted heterocyclic ring, H, OH, halogen, or a substituent group;
with the proviso that, when Ar is 4-isopropyl pyridine or 4-isopropenyl pyridine, R'" is hydrogen, and R"" is hydrogen, then R" can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms; when Ar is 4-isopropyl toluene or 4-isopropenyl toluene, and both R'" and R"" are hydrogen, R" can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms; when R" is C(CH3)2(CH2)5CH3, R2 and R4 are methyl, then R' and R" can not be H, OH or OCH3.
12. The pharmaceutical preparation of claim 11 wherein only one of R", R'" and R"" comprises Y-D D2-T2 and the others of R", R"' and R"" each independently comprise H, halogen, alkyl, alkoxy or a substituent group.
13. The pharmaceutical preparation of claim 11 , wherein:
R'" comprises H, halogen, C(haIogen)3, lower alkyl or alkoxy;
R"" comprises H, halogen, C(halogen)3, lower alkyl or alkoxy; and
R" comprises -Y-D1-D2-T2,
Y comprises Y is optionally present and if present comprises O, S,
NH, N-alkyl, C=CH, C≡C, CH2, CH(CH3), C(CH3)2. a carbocyclic ring having 4 to 6 ring members or a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms,
Di is optionally present and if present comprises alkyl,
D2 comprises H, an alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring or a heteroaromatic ring, T2 is optionally present and if present comprises an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen or a substituent group.
14. A method of stimulating a cannabinoid receptor in an individual or animal comprising administering to the individual or animal a therapeutically effective amount of a therapeutically effective amount of at least one compound of formula I below, and physiologically acceptable salts thereof:
Figure imgf000036_0001
wherein, the "A" ring atoms of compound formula I comprise carbon and 0 to 2 nitrogen heteroatoms;
Ar is an aromatic ring, an aromatic ring comprising at least one substituent group, a heteroaromatic ring, a heteroaromatic ring comprising 1 to 5 substituent groups, a heterocyclic ring or a heterocyclic ring comprising at least one substituent group;
R comprises H, OH, OCH3, alkoxy, OCH2CH2OH, alcohol, NH2, P03H, OPO3H, OSO3H, halogen, C(halogen)3, SEι, OE1 orNE1E2, E1 and E2 are each independently H or alkyl;
R' comprises H, OH, alkoxy, OCH2CH2OH, alcohol, NH2, PO3H, OPO3H, OSO3H, halogen, C(haIogen)3- SE.,, OE-i orNEιE2,
E1 and E2 are each independently H or alkyl;
R", R'" and R"" each independently comprises Y-Dι-D2-T2, H, halogen, alkyl, alkoxy or a substituent group, Y is optionally present and if present comprises O, S, NH, N-alkyl, C=CH,
C≡C, CH2, CH(CH3), C(CH3)2, a carbocyclic ring having 4 to 6 ring members or a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms,
Di is optionally present and if present comprises alkyl,
D2 comprises H, alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic, a tricyclic ring, an aromatic or heteroaromatic ring,
T2 is optionally present and if present comprises an aromatic ring, a substituted aromatic ring, a heteroaromatic ring, a substituted heteroaromatic ring, a heterocyclic ring, a substituted heterocyclic ring, H, OH, halogen, or a substituent group;
with the proviso that, when Ar is 4-isopropyl pyridine or 4-isopropenyl pyridine, R'" is hydrogen, and R"" is hydrogen, then R" can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms; when Ar is 4-isopropyl toluene or 4-isopropenyl toluene, and both R'" and R"" are hydrogen, R" can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms; when R" is C(CH3)2(CH2)5CH3, R2 and R4 are methyl, then R' and R" can not be H, OH or OCH3.
15. The method of claim 14 wherein:
R"' comprises H, halogen, C(halogen)3, lower alkyl or alkoxy; R"" comprises H, halogen, C(halogen)3, lower alkyl or alkoxy; and R" comprises -Y-Dι-D2-T2,
Y comprises Y is optionally present and if present comprises O, S, NH, N-alkyl, C=CH, C≡C, CH2, CH(CH3), C(CH3)2, a carbocyclic ring having 4 to 6 ring members or a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms,
Di is optionally present and if present comprises alkyl, D2 comprises H, an alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring or a heteroaromatic ring,
T2 is optionally present and if present comprises an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen or a substituent group.
16. A method of selectively stimulating CB2 cannabinoid receptors in an individual or animal comprising administering to the individual or animal a therapeutically effective amount of at least one compound of formula I below, and physiologically acceptable salts thereof:
Figure imgf000038_0001
wherein, the "A" ring atoms of compound formula I comprise carbon and 0 to 2 nitrogen heteroatoms;
Ar is an aromatic ring, an aromatic ring comprising at least one substituent group, a heteroaromatic ring, a heteroaromatic ring comprising 1 to 5 substituent groups, a heterocyclic ring or a heterocyclic ring comprising at least one substituent group;
R comprises H, OH, OCH3, alkoxy, OCH2CH2OH, alcohol, NH2, P03H, OP03H, OSO3H, halogen, C(halogen)3, SE1 ; OET or NEιE2, E1 and E2 are each independently H or alkyl;
R' comprises H, OH, alkoxy, OCH2CH2OH, alcohol, NH2, PO3H, OPO3H, OSO3H, halogen, C(halogen)3, SEι, OE-i orNE1E2,
E-i and E2 are each independently H or alkyl; R", R'" and R"" each independently comprises Y-Dι-D2-T2, H, halogen, alkyl, alkoxy or a substituent group,
Y is optionally present and if present comprises O, S, NH, N-alkyl, C=CH,
C≡C, CH2, CH(CH3), C(CH3)2, a carbocyclic ring having 4 to 6 ring members or a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms,
Di is optionally present and if present comprises alkyl,
D2 comprises H, alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic, a tricyclic ring, an aromatic or heteroaromatic ring,
T2 is optionally present and if present comprises an aromatic ring, a substituted aromatic ring, a heteroaromatic ring, a substituted heteroaromatic ring, a heterocyclic ring, a substituted heterocyclic ring, H, OH, halogen, or a substituent group;
with the proviso that, when Ar is 4-isopropyl pyridine or 4-isopropenyl pyridine, R'" is hydrogen, and R"" is hydrogen, then R" can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms; when Ar is 4-isopropyl toluene or 4-isopropenyl toluene, and both R'" and R"" are hydrogen, R" can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms; when R" is C(CH3)2(CH2)5CH3, R2 and R4 are methyl, then R' and R" can not be H, OH or OCH3.
17. The method of claim 16, wherein:
R'" comprises H, halogen, C(halogen)3, lower alkyl or alkoxy; R"" comprises H, halogen, C(halogen)3, lower alkyl or alkoxy; and R" comprises -Y-Dι-D2-T2,
Y comprises Y is optionally present and if present comprises O, S, NH, N-alkyl, C=CH, C≡C, CH2, CH(CH3), C(CH3)2, a carbocyclic ring having 4 to 6 ring members or a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms, Di is optionally present and if present comprises alkyl,
D2 comprises H, an alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring or a heteroaromatic ring,
T2 is optionally present and if present comprises an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen or a substituent group.
18. A method of treating a condition comprising administering to an individual or animal having the condition a therapeutically effective amount of at least one compound of formula I below, and physiologically acceptable salts thereof:
Figure imgf000040_0001
wherein, the "A" ring atoms of compound formula I comprise carbon and 0 to 2 nitrogen heteroatoms;
Ar is an aromatic ring, an aromatic ring comprising at least one substituent group, a heteroaromatic ring, a heteroaromatic ring comprising 1 to 5 substituent groups, a heterocyclic ring or a heterocyclic ring comprising at least one substituent group;
R comprises H, OH, OCH3, alkoxy, OCH2CH2OH, alcohol, NH2, P03H, OP03H, OSO3H, halogen, C(halogen)3, SEι, 0E-, or NEιE2, E1 and E2 are each independently H or alkyl;
R' comprises H, OH, alkoxy, OCH2CH2OH, alcohol, NH2, P03H, OPO3H, OSO3H, halogen, C(halogen)3, SEι, OE1 orNE1E2,
E1 and E2 are each independently H or alkyl; R", R'" and R"" each independently comprises Y-Dι-D2-T2, H, halogen, alkyl, alkoxy or a substituent group,
Y is optionally present and if present comprises O, S, NH, N-alkyl, C=CH,
C≡C, CH2, CH(CH3), C(CH3)2, a carbocyclic ring having 4 to 6 ring members or a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms,
Di is optionally present and if present comprises alkyl,
D2 comprises H, alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic, a tricyclic ring, an aromatic or heteroaromatic ring,
T2 is optionally present and if present comprises an aromatic ring, a substituted aromatic ring, a heteroaromatic ring, a substituted heteroaromatic ring, a heterocyclic ring, a substituted heterocyclic ring, H, OH, halogen, or a substituent group;
with the proviso that, when Ar is 4-isopropyl pyridine or 4-isopropenyl pyridine, R'" is hydrogen, and R"" is hydrogen, then R" can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms; when Ar is 4-isopropyl toluene or 4-isopropenyl toluene, and both R'" and R"" are hydrogen, R" can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms; when R" is C(CH3)2(CH2)5CH3) R2 and R4 are methyl, then R' and R" can not be H, OH or OCH3.
19. The method of claim 18, wherein:
R'" comprises H, halogen, C(halogen)3, lower alkyl or alkoxy; R"" comprises H, halogen, C(haIogen)3, lower alkyl or alkoxy; and R" comprises -Y-D1-D2-T2,
Y comprises Y is optionally present and if present comprises O, S, NH, N-alkyl, C=CH, C≡C, CH2, CH(CH3), C(CH3)2, a carbocyclic ring having 4 to 6 ring members or a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms, Di is optionally present and if present comprises alkyl,
D2 comprises H, an alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring or a heteroaromatic ring,
T2 is optionally present and if present comprises an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen or a substituent group.
20. A method of providing a physiological response in an individual or animal comprising administering to the individual or animal a therapeutically effective amount of at least one compound of formula I below, and physiologically acceptable salts thereof:
Figure imgf000042_0001
wherein, the "A" ring atoms of compound formula I comprise carbon and 0 to 2 nitrogen heteroatoms;
Ar is an aromatic ring, an aromatic ring comprising at least one substituent group, a heteroaromatic ring, a heteroaromatic ring comprising 1 to 5 substituent groups, a heterocyclic ring or a heterocyclic ring comprising at least one substituent group;
R comprises H, OH, OCH3, alkoxy, OCH2CH2OH, alcohol, NH2, P03H, OP03H, OSO3H, halogen, C(halogen)3, SE-t, OE-, orNEιE2, E1 and E2 are each independently H or alkyl;
R' comprises H, OH, alkoxy, OCH2CH2OH, alcohol, NH2, PO3H, OPO3H, OSO3H, halogen, C(halogen)3, SEL OE-! or NE1E2, Ei and E2 are each independently H or alkyl;
R", R™ and R"" each independently comprises Y-Dι-D2-T2, H, halogen, alkyl, alkoxy or a substituent group,
Y is optionally present and if present comprises O, S, NH, N-alkyl, C=CH,
C≡C, CH2, CH(CH3), C(CH3)2. a carbocyclic ring having 4 to 6 ring members or a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms,
Di is optionally present and if present comprises alkyl,
D2 comprises H, alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic, a tricyclic ring, an aromatic or heteroaromatic ring,
T2 is optionally present and if present comprises an aromatic ring, a substituted aromatic ring, a heteroaromatic ring, a substituted heteroaromatic ring, a heterocyclic ring, a substituted heterocyclic ring, H, OH, halogen, or a substituent group;
with the proviso that, when Ar is 4-isopropyl pyridine or 4-isopropenyl pyridine, R'" is hydrogen, and R"" is hydrogen, then R" can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms; when Ar is 4-isopropyl toluene or 4-isopropenyl toluene, and both R'" and R"" are hydrogen, R" can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms; when R" is C(CH3)2(CH2)5CH3, R2 and R4 are methyl, then R' and R" can not be H, OH or OCH3.
21. The method of claim 20, wherein:
R'" comprises H, halogen, C(halogen)3, lower alkyl or alkoxy; R"" comprises H, halogen, C(halogen)3, lower alkyl or alkoxy; and R" comprises -Y-D1-D2-T2,
Y comprises Y is optionally present and if present comprises O, S, NH, N-alkyl, C=CH, C≡C, CH2, CH(CH3), C(CH3)2. a carbocyclic ring having 4 to 6 ring members or a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms,
Di is optionally present and if present comprises alkyl,
D2 comprises H, an alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring or a heteroaromatic ring,
T2 is optionally present and if present comprises an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen or a substituent group.
22. A method of treating a condition selected from central and peripheral pain, neuropathy, neurodegenerative diseases including multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease; mental disorders such as schizophrenia and depression, endotoxic shock, hypotensive shock; or of modulating appetite; or of modulating the immune system; or of reducing fertility; or of treating diseases associated with motor function such as Tourette's syndrome; or of treating inflammation; or of providing neuroprotection; or of suppressing memory; or of producing peripheral vasodilation; or of treating epilepsy, glaucoma, nausea associated with cancer chemotherapy or nausea associated with Aids wasting syndrome comprising administering to an individual or animal having the condition a therapeutically effective amount of at least one compound at least one compound of formula I below, and physiologically acceptable salts thereof:
Figure imgf000044_0001
wherein, the "A" ring atoms of compound formula I comprise carbon and 0 to 2 nitrogen heteroatoms; Ar is an aromatic ring, an aromatic ring comprising at least one substituent group, a heteroaromatic ring, a heteroaromatic ring comprising 1 to 5 substituent groups, a heterocyclic ring or a heterocyclic ring comprising at least one substituent group;
R comprises H, OH, OCH3, alkoxy, OCH2CH2OH, alcohol, NH2, P03H, OP03H, OSO3H, halogen, C(halogen)3, SE^ OE1 orNEιE2, E1 and E2 are each independently H or alkyl;
R' comprises H, OH, alkoxy, OCH2CH2OH, alcohol, NH2, P03H, OPO3H, OSO3H, halogen, C(halogen)3, SE1, OE1 or NEιE2,
E1 and E2 are each independently H or alkyl;
R", R'" and R"" each independently comprises Y-Dι-D2-T2, H, halogen, alkyl, alkoxy or a substituent group,
Y is optionally present and if present comprises O, S, NH, N-alkyl, C=CH,
C≡C, CH2, CH(CH3), C(CH3)2, a carbocyclic ring having 4 to 6 ring members or a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms,
Di is optionally present and if present comprises alkyl,
D2 comprises H, alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic, a tricyclic ring, an aromatic or heteroaromatic ring,
T2 is optionally present and if present comprises an aromatic ring, a substituted aromatic ring, a heteroaromatic ring, a substituted heteroaromatic ring, a heterocyclic ring, a substituted heterocyclic ring, H, OH, halogen, or a substituent group;
with the proviso that, when Ar is 4-isopropyl pyridine or 4-isopropenyl pyridine, R'" is hydrogen, and R"" is hydrogen, then R" can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms; when Ar is 4-isopropyl toluene or 4-isopropenyl toluene, and both R'" and R"" are hydrogen, R" can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms; when R" is C(CH3)2(CH2)5CH3, R2 and R4 are methyl, then R' and R" can not be H, OH or OCH3.
23. The method of claim 22, wherein:
R'" comprises H, halogen, C(halogen)3, lower alkyl or alkoxy;
R"" comprises H, halogen, C(halogen)3, lower alkyl or alkoxy; and
R" comprises -Y-Dι-D2-T2,
Y comprises Y is optionally present and if present comprises O, S,
NH, N-alkyl, C=CH, C≡C, CH2, CH(CH3), C(CH3) , a carbocyclic ring having 4 to 6 ring members or a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms,
Di is optionally present and if present comprises alkyl,
D2 comprises H, an alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring or a heteroaromatic ring,
T2 is optionally present and if present comprises an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen or a substituent group.
PCT/US2003/026585 2002-08-23 2003-08-25 Novel biphenyl and biphenyl-like cannabinoids WO2004017920A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2004531188A JP2005536554A (en) 2002-08-23 2003-08-25 Novel biphenyl and biphenyl-like cannabinoids
CA002495903A CA2495903A1 (en) 2002-08-23 2003-08-25 Novel biphenyl and biphenyl-like cannabinoids
AU2003265659A AU2003265659A1 (en) 2002-08-23 2003-08-25 Novel biphenyl and biphenyl-like cannabinoids
EP03793389A EP1542948A4 (en) 2002-08-23 2003-08-25 Novel biphenyl and biphenyl-like cannabinoids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40560802P 2002-08-23 2002-08-23
US60/405,608 2002-08-23

Publications (3)

Publication Number Publication Date
WO2004017920A2 true WO2004017920A2 (en) 2004-03-04
WO2004017920A3 WO2004017920A3 (en) 2004-07-08
WO2004017920B1 WO2004017920B1 (en) 2004-09-10

Family

ID=31946905

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/026585 WO2004017920A2 (en) 2002-08-23 2003-08-25 Novel biphenyl and biphenyl-like cannabinoids

Country Status (7)

Country Link
US (1) US20040087590A1 (en)
EP (1) EP1542948A4 (en)
JP (1) JP2005536554A (en)
CN (1) CN1671639A (en)
AU (1) AU2003265659A1 (en)
CA (1) CA2495903A1 (en)
WO (1) WO2004017920A2 (en)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004085385A3 (en) * 2003-03-20 2004-11-25 Schering Corp Cannabinoid receptor ligands
EP1623741A2 (en) 2004-07-22 2006-02-08 Cadila Healthcare Ltd. Cannabinoid receptor ligands for hair growth modulation
WO2006041841A1 (en) * 2004-10-05 2006-04-20 Adolor Corporation Phenyl derivatives and methods of use
WO2006067450A2 (en) * 2004-12-21 2006-06-29 Ucl Biomedica Plc Modulator
US7297796B2 (en) 2004-10-13 2007-11-20 Adolor Corporation Sulfamoyl benzamide derivatives and methods of their use
US7544676B2 (en) 2005-11-10 2009-06-09 Adolor Corporation Sulfamoyl benzamides and methods of their use
US7696382B2 (en) 2004-02-20 2010-04-13 University College London Modulator
US7834037B2 (en) 2005-11-04 2010-11-16 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US7994179B2 (en) 2007-12-20 2011-08-09 Astrazeneca Ab Carbamoyl compounds as DGAT1 inhibitors 190
US8003676B2 (en) 2006-05-30 2011-08-23 Astrazeneca Ab 1,3,4-oxadiazole derivatives as DGAT1 inhibitors
US8053440B2 (en) 2007-02-01 2011-11-08 Resverlogix Corporation Compounds for the prevention and treatment of cardiovascular diseases
WO2012011112A1 (en) * 2010-07-22 2012-01-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Non psychoactive cannabinoids and uses thereof
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
US8188092B2 (en) 2009-06-19 2012-05-29 Astrazeneca Ab Substituted pyrazines as DGAT-1 inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US8410109B2 (en) 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US8772495B2 (en) 2008-05-23 2014-07-08 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein inhibitor
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9238640B2 (en) 2009-03-18 2016-01-19 Resverlogix Corp. Anti-inflammatory agents
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
US9610251B2 (en) 2011-11-01 2017-04-04 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9975886B1 (en) 2017-01-23 2018-05-22 Cadent Therapeutics, Inc. Potassium channel modulators
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
US10457679B2 (en) 2015-09-17 2019-10-29 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
US11603523B2 (en) 2019-01-18 2023-03-14 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
US11827610B2 (en) 2021-09-15 2023-11-28 Enko Chem, Inc. Protoporphyrinogen oxidase inhibitors
US11926616B2 (en) 2018-03-08 2024-03-12 Incyte Corporation Aminopyrazine diol compounds as PI3K-γ inhibitors

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999057106A1 (en) 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
AU778159B2 (en) 1999-10-18 2004-11-18 University Of Connecticut, The Peripheral cannabinoid receptor (CB2) selective ligands
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US6943266B1 (en) 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US6900236B1 (en) * 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US7119108B1 (en) * 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
CA2435409A1 (en) 2001-01-26 2002-08-01 University Of Connecticut Novel cannabimimetic ligands
US7173027B2 (en) 2001-01-29 2007-02-06 University Of Connecticut Receptor selective cannabimimetic aminoalkylindoles
JP4312594B2 (en) * 2001-07-13 2009-08-12 ユニバーシティ オブ コネチカット Novel bicyclic and tricyclic cannabinoids
US7666867B2 (en) * 2001-10-26 2010-02-23 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
AU2003265663A1 (en) 2002-08-23 2004-03-11 University Of Connecticut Keto cannabinoids with therapeutic indications
WO2005123053A2 (en) * 2004-06-22 2005-12-29 Pharmos Limited Use of cb2 receptors agonists for the treatment of huntington’s disease
HN2005000795A (en) * 2004-10-15 2010-08-19 Aventis Pharma Inc PYRIMIDINS AS ANTAGONISTS OF PROSTAGLANDINA D2 RECEPTOR
CN101668425A (en) * 2007-03-02 2010-03-10 田纳西州立大学研究基金会 Tri-aryl/heteroaroaromatic cannabinoids and use thereof
WO2009143183A1 (en) 2008-05-19 2009-11-26 University Of Tennessee Research Foundation, The Pyrimidine non-classical cannabinoid compounds and related methods of use
US8389534B2 (en) * 2008-05-19 2013-03-05 The University Of Tennessee Research Foundation Pyrimidine non-classical cannabinoid compounds and related methods of use
CA2724733A1 (en) * 2008-05-19 2009-11-26 The University Of Tennessee Research Foundation Pyrimidine classical cannabinoid compounds and related methods of use
JP2011520973A (en) 2008-05-19 2011-07-21 ユニヴァーシティ オブ テネシー リサーチ ファウンデーション，ザ Nonclassical cannabinoid compounds of pyridine and related methods of use
US10800726B2 (en) 2014-06-30 2020-10-13 The Uab Research Foundation Rexinoid compounds and methods of using rexinoid compounds for treating metabolic disorders and cancer
JP2019014675A (en) * 2017-07-06 2019-01-31 Dic株式会社 Phenyl phenol derivative and method for producing dibenzofuran derivative using the same
CN112047973B (en) * 2019-06-06 2022-11-18 上海科技大学 Cannabinoids compound, preparation method, composition and application thereof
CN114901071A (en) 2019-11-08 2022-08-12 维拉生物科技有限公司 Peripherally acting compositions containing Cannabidiol (CBD) and their use for enhancing female sexual function or treating female sexual disorders
CN111253222A (en) * 2020-03-02 2020-06-09 福建省中科生物股份有限公司 Phenolic compound ZKYY-037 and preparation method and application thereof
CN112500293B (en) * 2020-12-10 2022-10-18 福建省中科生物股份有限公司 1,1' -biphenyl-2, 6-diphenol compound and application thereof
CN114605236B (en) * 2022-03-16 2023-12-29 福建省中科生物股份有限公司 Biaryl phenol compound and pharmaceutical composition, preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550214A (en) * 1981-01-05 1985-10-29 Polaroid Corporation Blocked vinyl biphenyl compounds
US5053548A (en) * 1989-02-08 1991-10-01 Otsuka Pharmaceutical Company, Ltd. Biphenyl derivative composition for nerve cell degeneration repairing or protective agent and process for preparing a phenyl derivative contained in the composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018777A (en) * 1975-11-14 1977-04-19 Abbott Laboratories 2-Substituted-5-alkyl resorcinols
US4147872A (en) * 1977-09-13 1979-04-03 Pfizer Inc. 3-[2-Hydroxy-4-(substituted)-phenyl]azacycloalkanes and derivatives thereof as analgesic agents and intermediates therefor
JPS5798228A (en) * 1980-12-10 1982-06-18 Hisamitsu Pharmaceut Co Inc Biphenyl derivative
US4529732A (en) * 1983-03-14 1985-07-16 Pfizer Inc. 2-[2-Hydroxy-4-(substituted)phenyl]piperidines
US4792570A (en) * 1984-04-06 1988-12-20 Syntex (U.S.A.) Inc. 3- and 4-biphenyloxyaminoalkanes and related compounds as anti-inflammatory and analgetic agents
PH30449A (en) * 1991-11-25 1997-05-28 Lilly Co Eli Substituted phenyl phenol leukotriene antagonists
US5910505A (en) * 1997-03-21 1999-06-08 Eli Lilly And Company Leukotriene antagonists for use in the treatment or inhibition of oral squamous cell carcinoma
WO1999057106A1 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
US6943266B1 (en) * 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US6900236B1 (en) * 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550214A (en) * 1981-01-05 1985-10-29 Polaroid Corporation Blocked vinyl biphenyl compounds
US5053548A (en) * 1989-02-08 1991-10-01 Otsuka Pharmaceutical Company, Ltd. Biphenyl derivative composition for nerve cell degeneration repairing or protective agent and process for preparing a phenyl derivative contained in the composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1542948A2 *

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004085385A3 (en) * 2003-03-20 2004-11-25 Schering Corp Cannabinoid receptor ligands
US7642272B2 (en) 2003-03-20 2010-01-05 Schering Corporation Cannabinoid receptor ligands
US7696382B2 (en) 2004-02-20 2010-04-13 University College London Modulator
US9120723B2 (en) 2004-02-20 2015-09-01 Canbex Therapeutics Limited Modulator
US8293796B2 (en) 2004-02-20 2012-10-23 University College London Modulator
EP1623741A2 (en) 2004-07-22 2006-02-08 Cadila Healthcare Ltd. Cannabinoid receptor ligands for hair growth modulation
WO2006041841A1 (en) * 2004-10-05 2006-04-20 Adolor Corporation Phenyl derivatives and methods of use
JP2008515897A (en) * 2004-10-05 2008-05-15 アドラー コーポレーション Phenyl derivatives and methods of using the same
CN101035758B (en) * 2004-10-05 2010-12-01 阿得罗公司 Phenyl derivatives and methods of use
US7671052B2 (en) 2004-10-05 2010-03-02 Adolor Corporation Phenyl derivatives and methods of use
US7297796B2 (en) 2004-10-13 2007-11-20 Adolor Corporation Sulfamoyl benzamide derivatives and methods of their use
WO2006067450A3 (en) * 2004-12-21 2006-09-14 Ucl Biomedica Plc Modulator
WO2006067450A2 (en) * 2004-12-21 2006-06-29 Ucl Biomedica Plc Modulator
US8410109B2 (en) 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
US7834037B2 (en) 2005-11-04 2010-11-16 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8841295B2 (en) 2005-11-04 2014-09-23 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7544676B2 (en) 2005-11-10 2009-06-09 Adolor Corporation Sulfamoyl benzamides and methods of their use
US8003676B2 (en) 2006-05-30 2011-08-23 Astrazeneca Ab 1,3,4-oxadiazole derivatives as DGAT1 inhibitors
US8889698B2 (en) 2007-02-01 2014-11-18 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
US10532054B2 (en) 2007-02-01 2020-01-14 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
US8053440B2 (en) 2007-02-01 2011-11-08 Resverlogix Corporation Compounds for the prevention and treatment of cardiovascular diseases
US9199990B2 (en) 2007-02-01 2015-12-01 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
US7994179B2 (en) 2007-12-20 2011-08-09 Astrazeneca Ab Carbamoyl compounds as DGAT1 inhibitors 190
US8772495B2 (en) 2008-05-23 2014-07-08 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein inhibitor
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
US9238640B2 (en) 2009-03-18 2016-01-19 Resverlogix Corp. Anti-inflammatory agents
US11407719B2 (en) 2009-03-18 2022-08-09 Resverlogix Corp. Anti-inflammatory agents
US10882828B2 (en) 2009-03-18 2021-01-05 Resverlogix Corp. Anti-inflammatory agents
US10131640B2 (en) 2009-03-18 2018-11-20 Resverlogix Corp. Anti-inflammatory agents
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
US8188092B2 (en) 2009-06-19 2012-05-29 Astrazeneca Ab Substituted pyrazines as DGAT-1 inhibitors
WO2012011112A1 (en) * 2010-07-22 2012-01-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Non psychoactive cannabinoids and uses thereof
US9610251B2 (en) 2011-11-01 2017-04-04 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
US10016426B2 (en) 2011-11-01 2018-07-10 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9278940B2 (en) 2012-11-21 2016-03-08 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
US10772894B2 (en) 2015-03-13 2020-09-15 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
US10457679B2 (en) 2015-09-17 2019-10-29 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
US10882858B2 (en) 2015-09-17 2021-01-05 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
US11613539B2 (en) 2015-09-17 2023-03-28 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
US10717728B2 (en) 2017-01-23 2020-07-21 Cadent Therapeutics, Inc. Potassium channel modulators
US10351553B2 (en) 2017-01-23 2019-07-16 Cadent Therapeutics, Inc. Potassium channel modulators
US9975886B1 (en) 2017-01-23 2018-05-22 Cadent Therapeutics, Inc. Potassium channel modulators
US11926616B2 (en) 2018-03-08 2024-03-12 Incyte Corporation Aminopyrazine diol compounds as PI3K-γ inhibitors
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
US11603523B2 (en) 2019-01-18 2023-03-14 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
US11827610B2 (en) 2021-09-15 2023-11-28 Enko Chem, Inc. Protoporphyrinogen oxidase inhibitors

Also Published As

Publication number Publication date
EP1542948A2 (en) 2005-06-22
US20040087590A1 (en) 2004-05-06
CN1671639A (en) 2005-09-21
JP2005536554A (en) 2005-12-02
WO2004017920B1 (en) 2004-09-10
EP1542948A4 (en) 2008-12-17
WO2004017920A3 (en) 2004-07-08
AU2003265659A1 (en) 2004-03-11
CA2495903A1 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
US20040087590A1 (en) Novel biphenyl and biphenyl-like cannabinoids
US7285683B2 (en) Bicyclic and tricyclic cannabinoids
EP3459925B1 (en) Method for preparing 2-hydroxyl-4-(2, 3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative
KR100196356B1 (en) Diabetes mellitus-treating agent
US7666867B2 (en) Heteroindanes: a new class of potent cannabimimetic ligands
JP2005255685A (en) New pyrazole analog acting on cannabinoid receptor
JP2005507875A (en) Novel pyrazole analogues acting on cannabinoid receptors
WO2003084930A1 (en) Diphenylpyridine derivatives, the preparation thereof, and pharmaceutical compositions containing said derivatives
JPH10504836A (en) Ortho-substituted aromatic ether compounds and their use in pharmaceutical compositions for analgesia
JP2000500498A (en) Substituted aryl or heteroaryl amides with retinoid-like biological activity
JP2008526887A (en) Novel heteropyrrole analogs that act on cannabinoid receptors
EP1076653A2 (en) Novel cannabinoids selective for the cb2 receptor
EP1641758B1 (en) Diphenylpyridine derivatives, preparation and therapeutic application thereof
JP6950534B2 (en) Tetrahydronaphthalene derivative
WO2001028329A1 (en) Peripheral cannabinoid receptor (cb2) selective ligands
US7446229B2 (en) Bicyclic cannabinoids
EP1678159A2 (en) Thiophene-2-carboxamide derivatives and use thereof as cannabinoid cb-1 receptor antagonists
JP4762917B2 (en) Non-nucleoside reverse transcriptase inhibitors
JPH0686431B2 (en) Substituted tetralins, chromans and related compounds for the treatment of asthma
JP6734294B2 (en) Compositions for the treatment of fibrosis and conditions associated with fibrosis
JPS6160609A (en) Lipoxygenase inhibitor
JP2016514714A (en) Urea derivatives and their use as fatty acid binding protein (FABP) inhibitors
AU2004200538B2 (en) Novel bicyclic and tricyclic cannabinoids
JP2008543741A (en) New compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Effective date: 20040722

WWE Wipo information: entry into national phase

Ref document number: 2003265659

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003818057X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2003793389

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2495903

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004531188

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003793389

Country of ref document: EP